ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR- alpha (TNF- alpha ) EXPRESSION

Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor- alpha (TNF- alpha ). Antisense oligonucleotides targeted to nucleic acids encoding TNF- alpha are preferred. Methods of using these oligonucleotides for inhibition of TNF- alpha expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF- alpha are provided.

Description: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION This invention relates to compositions and methods for modulating expression of the human tumor necrosis factor-α (TNF-α) gene, which encodes a naturally present cytokine involved in regulation of immune function and implicated in infectious and inflammatory disease. This invention is also directed to methods for inhibiting TNF-α mediated immune responses; these methods can be used diagnostically or therapeutically. Furthermore, this invention is directed to treatment of conditions associated with expression of the human TNF-α gene. BACKGROUND OF THE INVENTION Tumor necrosis factor α (TNF-α also cachectin) is an important cytokine that plays a role in host defense. The cytokine is produced primarily in macrophages and monocytes in response to infection, invasion, injury, or inflammation. Some examples of inducers of TNF-α include bacterial endotoxins, bacteria, viruses, lipopolysaccharide (LPS) and cytokines including GM-CSF, IL-1, IL-2 and IFN-γ. TNF-α interacts with two different receptors, TNF receptor I (TNFRI, p55) and TNFRII (p75) , in order to transduce its effects, the net result of which is altered gene expression. Cellular factors induced by TNF-α include interleukin-1 (IL-1) , interleukin-6 (IL-6) , interleukin-8 (IL-8) , interferon-γ (IFN-γ) , platelet derived growth factor (PDGF) and epidermal growth factor (EGF) , and endothelial cell adhesion molecules including endothelial leukocyte adhesion molecule 1 (ELAM-1) , intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCA -1) (Tracey,K.J. , et al . , Annu . Rev. Cell Biol . , 1993, 9, 317-343; Arvin,B., et al . , Ann . NY Acad. Sci . , 1995, 755, 62-71) . Despite the protective effects of the cytokine, overexpression of TNF-α often results in disease states, particularly in infectious, inflammatory and autoimmune diseases. This process may involve the apoptotic pathways (Ksontini,R. , et al . , J. Immunol . , 1998, 160, 4082-4089). High levels of plasma TNF-α have been found in infectious diseases such as sepsis syndrome, bacterial meningitis, cerebral malaria, and AIDS; autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease (including Crohn's disease), sarcoidosis, multiple sclerosis, Kawasaki syndrome, graft-versus-host disease and transplant (allograft) rejection; and organ failure conditions such as adult respiratory distress syndrome, congestive heart failure, acute liver failure and myocardial infarction (Eigler,A., et al . , Immunol . Today, 1997, 18, 487-492). Other diseases in which TNF-α is involved include asthma (Shah, A., et al . , Clinical and Experimental Allergy, 1995, 25, 1038-1044), brain injury following ischemia (Arvin,B., et al . , Ann . NY Acad. Sci . , 1995, 765, 62-71), non-insulin- dependent diabetes mellitus (Hotamisligil,G.S. , et al . , Science, 1993, 259, 87-90), insulin-dependent diabetes mellitus (Yang,X.-D., et al . , J. Exp. Med. , 1994, 180, 995- 1004), hepatitis (Ksontini,R. , et al . , J. Immunol . , 1998, 160, 4082-4089), atopic dermatitis (Sumimoto, S. , et al . , Arch . Dis . Child. , 1992, 67, 277-279), and pancreatitis (Norman, J.G. , et al . , Surgery, 1996, 120, 515-521). Further, inhibitors of TNF-α have been suggested to be useful for cancer prevention (Suganuma, M. , et al . { Cancer Res . , 1996, 56, 3711-3715). Elevated TNF-α expression may also play a role in obesity (Kern, P.A., J " . Nutr. , 1997, 127, 1917S-1922S) . TNF-α was found to be expressed in human adipocytes and increased expression, in general, correlated with obesity. There are currently several approaches to inhibiting TNF-α expression. Approaches used to treat rheumatoid arthritis include a chimeric anti-TNF-α antibody, a humanized monoclonal anti-TNF-α antibody, and recombinant human soluble TNF-α receptor (Camussi,G., Drugs, 1998, 55, 613-620) . Other examples are indirect TNF-α inhibitors including phosphodiesterase inhibitors (e.g. pentoxifylline) and metalloprotease inhibitors (Eigler,A., et al . , Immunol . Today, 1997, 18, 487-492). An additional class of direct TNF-α inhibitors is oligonucleotides, including triplex-forming oligonucleotides, ribozymes, and antisense oligonucleotides . Several publications describe the use of oligonucleotides targeting TNF-α by non-antisense mechanisms. U.S. Patent 5,650,316, WO 95/33493 and Aggarwal,B.B. et al . { Cancer Research, 1996, 56, 5156-5164) disclose triplex-forming oligonucleotides targeting TNF-α. WO 95/32628 discloses triplex-forming oligonucleotides especially those possessing one or more stretches of guanosine residues capable of forming secondary structure. WO 94/10301 discloses ribozyme compounds active against TNF-α mRNA. WO 95/23225 discloses enzymatic nucleic acid molecules active against TNF-α mRNA. A number of publications have described the use of antisense oligonucleotides targeting nucleic acids encoding TNF-α. The TNF-α gene has four exons and three introns. WO 93/09813 discloses TNF-α antisense oligonucleotides conjugated to a radioactive moiety, including sequences targeted to the 5'-UTR, AUG start site, exon 1, and exon 4 including the stop codon of human TNF-α. EP 0 414 607 Bl discloses antisense oligonucleotides targeting the AUG start codon of human TNF-α. WO 95/00103 claims antisense oligonucleotides to human TNF-α including sequences targeted to exon 1 including the AUG start site. Hartmann,G. et al . (Mol . Med. , 1996, 2, 429-438) disclose uniform phosphorothioates and mixed backbone phosphorothioate/ phosphodiester oligonucleotides targeted to the AUG start site of human TNF-α. Hartmann,G. et al . {Antisense Nucleic Acid Drug Devel . , 1996, 6, 291-299) disclose antisense phosphorothioate oligonucleotides targeted to the AUG start site, the exon 1/intron 1 junction, and exon 4 of human TNF-α. d'Hellencourt,C.F. et al . {Biochim. Biophys . Acta , 1996, 1317, 168-174) designed and tested a series of unmodified oligonucleotides targeted to the 5'-UTR, and exon 1, including the AUG start site, of human TNF-α. Additionally, one oligonucleotide each was targeted to exon 4 and the 3 ' -UTR of human TNF-α and one oligonucleotide was targeted to the AUG start site of mouse TNF-α. Rojanasakul, Y. et al . {J. Biol . Chem. , 1997, 272, 3910-3914) disclose an antisense phosphorothioate oligonucleotide targeted to the AUG start site of mouse TNF-α. Taylor, M.F. et al . {J. Biol . Chem. , 1996, 271 , 17445-17452 and Antisense Nucleic Acid Drug Devel . , 1998, 8, 199-205) disclose morpholino, methyl-morpholino, phosphodiester and phosphorothioate oligonucleotides targeted to the 5 ' -UTR and AUG start codon of mouse TNF-α. Tu,G.-C. et al . {J. Biol . Chem. , 1998, 273 , 25125-25131) designed and tested 42 phosphorothioate oligonucleotides targeting sequences throughout the rat TNF-α gene. Interestingly, some phosphorothioate oligodeoxynucleotides have been found to enhance lipopolysaccharide-stimulated TNF-α synthesis up to four fold due to nonspecific immunostimulatory effects (Hartmann et al . Mol . Med. , 1996, 2, 429-438). Accordingly, there remains an unmet need for therapeutic compositions and methods for inhibiting expression of TNF-α, and disease processes associated therewith. BRIEF DESCRIPTION OF THE INVENTION The present invention provides oligonucleotides which are targeted to nucleic acids encoding TNF-α and are capable of modulating TNF-α expression. The present invention also provides chimeric oligonucleotides targeted to nucleic acids encoding human TNF-α. The oligonucleotides of the invention are believed to be useful both diagnostically and therapeutically, and are believed to be particularly useful in the methods of the present invention. The present invention also comprises methods of modulating the expression of human TNF-α, in cells and tissues, using the oligonucleotides of the invention. Methods of inhibiting TNF-α expression are provided; these methods are believed to be useful both therapeutically and diagnostically. These methods are also useful as tools, for example, for detecting and determining the role of TNF- α in various cell functions and physiological processes and conditions and for diagnosing conditions associated with expression of TNF-α. The present invention also comprises methods for diagnosing and treating infectious and inflammatory diseases, particularly diabetes, rheumatoid arthritis, Crohn's disease, pancreatitis, multiple sclerosis, atopic dermatitis and hepatitis. These methods are believed to be useful, for example, in diagnosing TNF-α-associated disease progression. These methods employ the oligonucleotides of the invention. These methods are believed to be useful both therapeutically, including prophylactically, and as clinical research and diagnostic tools. DETAILED DESCRIPTION OF THE INVENTION TNF-α plays an important regulatory role in the immune response to various foreign agents. Overexpression of TNF- α results in a number of infectious and inflammatory diseases. As such, this cytokine represents an attractive target for treatment of such diseases. In particular, modulation of the expression of TNF-α may be useful for the treatment of diseases such as Crohn's disease, diabetes mellitus, multiple sclerosis, rheumatoid arthritis, hepatitis, pancreatitis and asthma. The present invention employs antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding TNF-α, ultimately modulating the amount of TNF-α produced. This is accomplished by providing oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding TNF-α. This relationship between an antisense compound such as an oligonucleotide and its complementary nucleic acid target, to which it hybridizes, is commonly referred to as "antisense". "Targeting" an oligonucleotide to a chosen nucleic acid target, in the context of this invention, is a multistep process. The process usually begins with identifying a nucleic acid sequence whose function is to be modulated. This may be, as examples, a cellular gene (or mRNA made from the gene) whose expression is associated with a particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the targets are nucleic acids encoding TNF-α; in other words, a gene encoding TNF-α, or mRNA expressed from the TNF-α gene. mRNA which encodes TNF-α is presently the preferred target. The targeting process also includes determination of a site or sites within the nucleic acid sequence for the antisense interaction to occur such that modulation of gene expression will result. In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form a region known to such persons as the 5 ' -untranslated region, the 3 ' -untranslated region, the 5' cap region and intron/exon junction ribonucleotides. Thus, oligonucleotides may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. The oligonucleotide may therefore be specifically hybridizable with a transcription initiation site region, a translation initiation codon region, a 5' cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5 ' - or 3 ' -untranslated region. Since, as is known in the art, the translation initiation codon is typically 5 ' -AUG (in transcribed mRNA molecules; 5 ' -ATG in the corresponding DNA molecule) , the translation initiation codon is also referred to as the "AUG codon, " the "start codon" or the "AUG start codon." A minority of genes have a translation initiation codon having the RNA sequence 5'- GUG, 5'-UUG or 5 ' -CUG, and 5 ' -AUA, 5 ' -ACG and 5 ' -CUG have been shown to function in vivo . Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (prokaryotes) . It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding TNF-α, regardless of the sequence (s) of such codons. It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5 ' -UAA, 5 ' -UAG and 5 ' -UGA (the corresponding DNA sequences are 5 ' -TAA, 5 '-TAG and 5 ' -TGA, respectively) . The terms "start codon region, " "AUG region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3 ' ) from a translation initiation codon. This region is a preferred target region. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3 ' ) from a translation termination codon. This region is a preferred target region. The open reading frame (ORF) or "coding region, " which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other preferred target regions include the 5' untranslated region (5 'UTR), known in the art to refer to the portion of an mRNA in the 5 ' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene and the 3' untranslated region (3 'UTR), known in the art to refer to the portion of an mRNA in the 3 ' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3 ' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5 ' -most residue of the mRNA via a 5 '-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region. Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a pre-mRNA transcript to yield one or more mature mRNAs. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., exon-exon or intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. Targeting particular exons in alternatively spliced mRNAs may also be preferred. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA. Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired modulation. "Hybridization" , in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them. "Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide . It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non- target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment or, in the case of in vi tro assays, under conditions in which the assays are conducted. Hybridization of antisense oligonucleotides with mRNA interferes with one or more of the normal functions of mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in by the RNA. Binding of specific protein (s) to -lithe RNA may also be interfered with by antisense oligonucleotide hybridization to the RNA. The overall effect of interference with mRNA function is modulation of expression of TNF-α. In the context of this invention "modulation" means either inhibition or stimulation; i.e., either a decrease or increase in expression. This modulation can be measured in ways which are routine in the art, for example by Northern blot assay of mRNA expression, or reverse transcriptase PCR, as taught in the examples of the instant application or by Western blot or ELISA assay of protein expression, or by an immunoprecipitation assay of protein expression. Effects of antisense oligonucleotides of the present invention on TNF-α expression can also be determined as taught in the examples of the instant application. Inhibition is presently a preferred form of modulation. The oligonucleotides of this invention can be used in diagnostics, therapeutics, prophylaxis, and as research reagents and in kits. Since the oligonucleotides of this invention hybridize to nucleic acids encoding TNF-α, sandwich, colorimetric and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotides with the TNF-α gene or mRNA can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of TNF-α may also be prepared. The present invention is also suitable for diagnosing abnormal inflammatory states in tissue or other samples from patients suspected of having an inflammatory disease such as rheumatoid arthritis. The ability of the oligonucleotides of the present invention to inhibit inflammatory processes may be employed to diagnose such states. A number of assays may be formulated employing the present invention, which assays will commonly comprise contacting a tissue sample with an oligonucleotide of the invention under conditions selected to permit detection and, usually, quantitation of such inhibition. In the context of this invention, to "contact" tissues or cells with an oligonucleotide or oligonucleotides means to add the oligonucleotide (s) , usually in a liquid carrier, to a cell suspension or tissue sample, either in vi tro or ex vivo, or to administer the oligonucleotide (s) to cells or tissues within an animal. The oligonucleotides of this invention may also be used for research purposes. Thus, the specific hybridization exhibited by the oligonucleotides may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally- occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases. The antisense compounds in accordance with this invention preferably comprise from about 5 to about 50 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides) . As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines . Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage. Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl- phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates , phosphoramidates including 3 '-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates , thionoalkylphosphonates , thionoalkylphosphotriesters, and boranophosphates having normal 3' -5' linkages, 2' -5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3' -5' to 5' -3' or 2' -5' to 5 '-2'. Various salts, mixed salts and free acid forms are also included. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to U.S. Patent 3,687,808 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897, 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131, 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677, 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111, 5,563,253; 5,571,799; 5,587,361; and 5 , 625 , 050. Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside) ; siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, 0, S and CH 2 component parts. Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439. In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA) . In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al . { Science, 1991, 254 , 1497-1500) . Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH 2 -NH-0-CH 2 -, -CH 2 -N(CH 3 ) -0-CH 2 - [known as a methylene (methylimino) or MMI backbone], -CH 2 -0-N(CH 3 ) -CH 2 - , -CH 2 -N(CH 3 ) -N(CH 3 )-CH 2 - and -O-N (CH 3 ) -CH 2 -CH 2 - [wherein the native phosphodiester backbone is represented as -O-P-O- CH 2 -] of the above referenced U.S. Patent 5,489,677, and the amide backbones of the above referenced U.S. Patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506. Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; 0- , S-, or N-alkyl, 0-alkyl-O-alkyl, 0-, S-, or N-alkenyl, or 0-, S- or N-alkynyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C x to C 10 alkyl or C 2 to C 10 alkenyl and alkynyl. Particularly preferred are 0[(CH 2 ) n O] m CH 3 , 0(CH 2 ) n OCH 3 , O (CH 2 ) 2 0N (CH 3 ) 2 , 0(CH 2 ) n NH 2, 0(CH 2 ) n CH 3# 0(CH 2 ) n ONH 2> and O (CH 2 ) n ON [ (CH 2 ) n CH 3 ) ] 2; where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C 1 to C 10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, 0- alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3, 0CF 3< SOCH 3, S0 2 CH 3ι ON0 2 N0 2, N 3 _ NH 2 heterocycloalkyl , heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2 ' -methoxyethoxy (2 ' -0-CH 2 CH 2 OCH 3 , also known as 2 ' -O- (2-methoxyethyl) or 2'-MOE) (Martin et al . , Helv. Chim. Acta 1995, 78, 486-504) i.e., an alkoxyalkoxy group . Other preferred modifications include 2 ' -methoxy (2 1 - 0-CH 3 ) , 2 ' -aminopropoxy (2 ' -OCH 2 CH 2 CH 2 NH 2 ) and 2'-fluoro (2'- F) . Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3 ' terminal nucleotide or in 2' -5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar " . Representative United States patents that teach the preparation of such modified sugars structures include, but are not limited to, U.S. Patent 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5 , 700 , 920. Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G) , and the pyrimidine bases thymine (T) , cytosine (C) and uracil (U) . Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C or m5c) , 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2- thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-ρropynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil) , 4-thiouracil, 8-halo, 8- amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8- substituted adenines and guanines, 5-halo particularly 5- bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8- azaguanine and 8-azaadenine, 7-deazaguanine and 7- deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in the Concise Encyclopedia Of Polymer Science And Engineering 1990, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, those disclosed by Englisch et al. (Angewandte Che ie, International Edition 1991, 30, 613-722), and those disclosed by Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds . , Antisense Research and Applications 1993, CRC Press, Boca Raton, pages 289-302. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5-Methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds . , Antisense Research and Applications 1993, CRC Press, Boca Raton, pages 276-278) and are presently preferred base substitutions, even more particularly when combined with 2 ' -O-methoxyethyl sugar modifications. Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well as U.S. Patent 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941. Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al . , Proc. Natl . Acad. Sci . USA 1989, 86, 6553-6556), cholic acid (Manoharan et al . , Bioorg. Med. Chem. Lett . 1994, 4 , 1053-1059), a thioether, e.g., hexyl- S-tritylthiol (Manoharan et al . , Ann . N. Y. Acad. Sci . 1992, 660, 306-309; Manoharan et al . , Bioorg. Med. Chem. Let . 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al . , Nucl . Acids Res. 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al . , EMBO J. 1991, 10, 1111-1118; Kabanov et al . , FEBS Lett . 1990, 259, 327-330; Svinarchuk et al . , Biochimie 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac- glycerol or triethylammonium 1, 2-di-O-hexadecyl- rac- glycero-3-H-phosphonate (Manoharan et al . , Tetrahedron Lett. 1995, 36, 3651-3654; Shea et al . , Nucl . Acids Res . 1990, 18, 3777-3783J, a polyamine or a polyethylene glycol chain (Manoharan et al . , Nucleosides & Nucleotides 1995, 14 , 969-973), or adamantane acetic acid (Manoharan et al . , Tetrahedron Lett. 1995, 36, 3651-3654) , a palmityl moiety (Mishra et al . , Biochim . Biophys . Acta 1995, 1264 , 229- 237) , or an octadecyla ine or hexylamino-carbonyl- oxycholesterol moiety (Crooke et al . , J. Pharmacol . Exp . Ther. 1996, 277, 923-937) . Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Patent 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923 5,599,928 and 5,688,941. The present invention also includes oligonucleotides which are chimeric oligonucleotides. "Chimeric" oligonucleotides or "chimeras," in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. This RNAse H- mediated cleavage of the RNA target is distinct from the use of ribozymes to cleave nucleic acids . Ribozymes are not comprehended by the present invention. Examples of chimeric oligonucleotides include but are not limited to "gapmers," in which three distinct regions are present, normally with a central region flanked by two regions which are chemically equivalent to each other but distinct from the gap. A preferred example of a gapmer is an oligonucleotide in which a central portion (the "gap") of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2 ' -deoxynucleotides, while the flanking portions (the 5' and 3' "wings") are modified to have greater affinity for the target RNA molecule but are unable to support nuclease activity (e.g., fluoro- or 2 ' -O-methoxyethyl-substituted) . Chimeric oligonucleotides are not limited to those with modifications on the sugar, but may also include oligonucleosides or oligonucleotides with modified backbones, e.g., with regions of phosphorothioate (P=S) and phosphodiester (P=0) backbone linkages or with regions of MMI and P=S backbone linkages. Other chimeras include "wingmers," also known in the art as "hemimers," that is, oligonucleotides with two distinct regions. In a preferred example of a wingmer, the 5' portion of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2 ' -deoxynucleotides, whereas the 3 ' portion is modified in such a fashion so as to have greater affinity for the target RNA molecule but is unable to support nuclease activity (e.g., 2'-fluoro- or 2 ' -O-methoxyethyl- substituted), or vice-versa. In one embodiment, the oligonucleotides of the present invention contain a 2 ' -O-methoxyethyl (2 ' -0-CH 2 CH 2 OCH 3 ) modification on the sugar moiety of at least one nucleotide. This modification has been shown to increase both affinity of the oligonucleotide for its target and nuclease resistance of the oligonucleotide. According to the invention, one, a plurality, or all of the nucleotide subunits of the oligonucleotides of the invention may bear a 2 ' -O- methoxyethyl (-0-CH 2 CH 2 OCH 3 ) modification. Oligonucleotides comprising a plurality of nucleotide subunits having a 2 ' - O-methoxyethyl modification can have such a modification on any of the nucleotide subunits within the oligonucleotide, and may be chimeric oligonucleotides. Aside from or in addition to 2 ' -O-methoxyethyl modifications, oligonucleotides containing other modifications which enhance antisense efficacy, potency or target affinity are also preferred. Chimeric oligonucleotides comprising one or more such modifications are presently preferred. The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and 2 ' -alkoxy or 2 ' -alkoxyalkoxy derivatives, including 2 ' -0- methoxyethyl oligonucleotides (Martin, P., Helv. Chim. Acta 1995, 78, 486-504) . It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling, VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides. The antisense compounds of the present invention include bioequivalent compounds, including pharmaceutically acceptable salts and prodrugs . This is intended to encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of the nucleic acids of the invention and prodrugs of such nucleic acids. "Pharmaceutically acceptable salts" are physiologically and pharmaceutically acceptable salts of the nucleic acids of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto (see, for example, Berge et al . , "Pharmaceutical Salts," J " . of Pharma Sci . 1977, 66, 1- 19) . For oligonucleotides, examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc. ; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; ® salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p- toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine. The oligonucleotides of the invention may additionally or alternatively be prepared to be delivered in a "prodrug" form. The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [ (S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510. For therapeutic or prophylactic treatment, oligonucleotides are administered in accordance with this invention. Oligonucleotide compounds of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the like in addition to the oligonucleotide. Such compositions and formulations are comprehended by the present invention. Pharmaceutical compositions comprising the oligonucleotides of the present invention may include penetration enhancers in order to enhance the alimentary delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i . e . , fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1991, 8, 91-192; Muranishi, Cri tical Reviews in Therapeutic Drug Carrier Systems 1990, 7, 1-33) . One or more penetration enhancers from one or more of these broad categories may be included. Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-rac-glycerol) , dilaurin, caprylic acid, arachidonic acid, glyceryl 1-monocaprate, l-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1991, page 92; Muranishi, Cri tical Reviews in Therapeutic Drug Carrier Systems 1990, 7, 1; El-Hariri et al . , J. Pharm. Pharmacol . 1992 44 , 651-654) . The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 Tn; Goodman & Gilman ' s The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al . , eds., McGraw-Hill, New York, NY, 1996, pages 934-935) . Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations. Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA) , citric acid, salicylates { e . g. , sodium salicylate, 5-methoxysalicylate and homovanilate) , N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1991, page 92; Muranishi, Cri tical Reviews in Therapeutic Drug Carrier Systems 1990, 7, 1-33; Buur et al . , J. Control Rel . 1990, 14 , 43-51). Chelating agents have the added advantage of also serving as DNase inhibitors . Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1991, page 92) ; and perfluorochemical emulsions, such as FC-43 (Takahashi et al . , J. Pharm. Pha acol . 1988, 40, 252-257). Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al . , Cri tical Reviews in Therapeutic Drug Carrier Systems 1991, page 92) ; and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al . , J. Pharm. Pharmacol . 1987, 39, 621-626) . As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. In contrast to a carrier compound, a "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal . The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc. , when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents { e . g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers { e . g. , lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates { e . g. , starch, sodium starch glycolate, etc.); or wetting agents { e. g. , sodium lauryl sulphate, etc.). Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are described in U.S. Patents 4,704,295; 4,556,552; 4,309,406; and 4,309,404. The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials such as, e. g. , antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the invention. Regardless of the method by which the oligonucleotides of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the in vivo stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid: oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layers made up of lipids arranged in a bilayer configuration (see, generally, Chonn et al . , Current Op . Biotech . 1995, 6, 698-708) . The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal, and transdermal) , oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2 ' -O-methoxyethyl modification are believed to be particularly useful for oral administration. Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Compositions for oral administration include powders or granules, suspensions or solutions in water or non- aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In some cases it may be more effective to treat a patient with an oligonucleotide of the invention in conjunction with other traditional therapeutic modalities in order to increase the efficacy of a treatment regimen. In the context of the invention, the term "treatment regimen" is meant to encompass therapeutic, palliative and prophylactic modalities. For example, a patient may be treated with conventional chemotherapeutic agents such as those used for tumor and cancer treatment. When used with the compounds of the invention, such chemotherapeutic agents may be used individually, sequentially, or in combination with one or more other such chemotherapeutic agents. The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC 50 s found to be effective in vi tro and in in vivo animal models. In general, dosage is from 0.01 μg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μg to 100 g per kg of body weight, once or more daily, to once every 20 years. Thus, in the context of this invention, by "therapeutically effective amount" is meant the amount of the compound which is required to have a therapeutic effect on the treated individual. This amount, which will be apparent to the skilled artisan, will depend upon the age and weight of the individual, the type of disease to be treated, perhaps even the gender of the individual, and other factors which are routinely taken into consideration when designing a drug treatment. A therapeutic effect is assessed in the individual by measuring the effect of the compound on the disease state in the animal. The following examples illustrate the present invention and are not intended to limit the same. EXAMPLES EXAMPLE 1: Synthesis of Oligonucleotides Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β-cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, CA) . For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of 3 H-1,2- benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step. Cytosines may be 5-methyl cytosines. (5-methyl deoxycytidine phosphoramidites available from Glen Research, Sterling, VA or Amersham Pharmacia Biotech, Piscataway, NJ) 2 ' -methoxy oligonucleotides are synthesized using 2'- methoxy β-cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham, MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds. Other 2 ' -alkoxy oligonucleotides are synthesized by a modification of this method, using appropriate 2 ' - modified amidites such as those available from Glen Research, Inc., Sterling, VA. 2'-fluoro oligonucleotides are synthesized as described in Kawasaki et al . {J. Med. Chem. 1993, 36, 831- 841). Briefly, the protected nucleoside N 6 -benzoyl-2 ' - deoxy-2 ' -fluoroadenosine is synthesized utilizing commercially available 9-β-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-α-fluoro atom is introduced by a S N 2- displacement of a 2 ' -β-O-trifyl group. Thus N 6 -benzoyl-9-β- D-arabinofuranosyladenine is selectively protected in moderate yield as the 3 ' , 5 ' -ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N 6 -benzoyl groups is accomplished using standard methodologies. Standard methods are also used to obtain the 5 ' -dimethoxytrityl- (DMT) and 5 ' -DMT-3 ' -phosphoramidite intermediates. The synthesis of 2 ' -deoxy-2 ' -fluoroguanosine is accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-β-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl- arabinofuranosylguanosine. Deprotection of the TPDS group is followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine . Selective O-deacylation and triflation is followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies are used to obtain the 5 ' -DMT- and 5 ' -DMT-3 ' -phosphoramidites. Synthesis of 2 ' -deoxy-2 ' -fluorouridine is accomplished by the modification of a known procedure in which 2, 2'- anhydro-1-β-D-arabinofuranosyluracil is treated with 70% hydrogen fluoride-pyridine. Standard procedures are used to obtain the 5 ' -DMT and 5 ' -DMT-3 'phosphoramidites. 2 ' -deoxy-2 ' -fluorocytidine is synthesized via amination of 2 ' -deoxy-2 ' -fluorouridine, followed by selective protection to give N 4 -benzoyl-2 ' -deoxy-2 ' - fluorocytidine. Standard procedures are used to obtain the 5 ' -DMT and 5 ' -DMT-3 'phosphoramidites . 2 •- (2-methoxyethyl) -modified amidites were synthesized according to Martin, P. {Helv. Chim. Acta 1995, 78, 486- 506) . For ease of synthesis, the last nucleotide may be a deoxynucleotide . 2 ' -0-CH 2 CH 2 OCH 3- cytosines may be 5-methyl cytosines . Synthesis of 5 -Methyl cytosine monomers: 2.2' -Anhydro fl- (β-D-arabinofuranosyl) -5-methyluridinel : 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M) , diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL) . The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L) , with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL) . The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 hours) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield) . The material was used as is for further reactions. 2 ' -O-Methoxyethyl-5-methyluridine: 2, 2 ' -Anhydro-5-methyluridine (195 g, 0.81 M), tris(2- methoxyethyUborate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL) . The residue was suspended in hot acetone (1 L) . The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH 3 CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH 2 Cl 2 /acetone/MeOH (20:5:3) containing 0.5% Et 3 NH. The residue was dissolved in CH 2 C1 2 (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. 2 ' -O-Methoxyethyl-5 ' -O-dimethoxytrityl-5-methyluridine : 2 ' -O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L) . A first aliquot of di- methoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH 3 CN (200 mL) . The residue was dissolved in CHC1 3 (1.5 L) and extracted with 2x500 mL of saturated NaHC0 3 and 2x500 mL of saturated NaCl . The organic phase was dried over Na 2 S0 4 , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et 3 NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%) . 3 ' -O-Acetyl-2 ' -O-methoxyethyl-5 ' -O-dimethoxytrityl-5- methyluridine : 2 ' -O-Methoxyethyl-5 ' -O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M) , DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours . The reaction was monitored by tic by first quenching the tic sample with the addition of MeOH. Upon completion of the reaction, as judged by tic, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHC1 3 (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHC1 3 . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product) . The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane (4 : 1) . Pure product fractions were evaporated to yield 96 g (84%) . 3 ' -O-Acetyl-2 ' -O-methoxyethyl-5 ' -O-dimethoxytrityl-5- methyl-4-triazoleuridine : A first solution was prepared by dissolving 3 ' -0- acetyl-2 ' -O-methoxyethyl-5 ' -O-dimethoxytrityl-5- methyluridine (96 g, 0.144 M) in CH 3 CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH 3 CN (1 L) , cooled to -5°C and stirred for 0.5 hours using an overhead stirrer. P0C1 3 was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours . The first solution was added dropwise, over a 45 minute period, to the later solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHC0 3 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound. 2' -O-Methoxyethyl-5' -O-dimethoxytrityl-5-methylcytidine: A solution of 3 ' -O-acetyl-2 ' -O-methoxyethyl-5 ' -0- dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH 4 OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL) . The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH 3 gas was added and the vessel heated to 100°C for 2 hours (tic showed complete conversion) . The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL) . The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound. N 4 -Benzoyl-2 ' -O-methoxyethyl-5 ' -O-dimethoxytrityl-5-methyl- cytidine: 2 ' -O-Methoxyethyl-5 ' -O-dimethoxytrityl-5-methyl- cytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tic showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL) . The residue was dissolved in CHC1 3 (700 mL) and extracted with saturated NaHC0 3 (2x300 mL) and saturated NaCl (2x300 mL) , dried over MgS0 4 and evaporated to give a residue (96 g) . The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et 3 NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound. N 4 -Benzoyl-2 ' -O-methoxyethyl-5 ' -0-dimethoxytrityl-5- methylcytidine- ' -amidite: N 4 -Benzoyl-2 ' -O-methoxyethyl-5 ' -0-dimethoxytrityl-5- methylcytidine (74 g, 0.10 M) was dissolved in CH 2 C1 2 (1 L) . Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy- tetra(isopropyl) phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tic showed the reaction to be 95% complete) . The reaction mixture was extracted with saturated NaHC0 3 (1x300 mL) and saturated NaCl (3x300 mL) . The aqueous washes were back- extracted with CH 2 C1 2 (300 mL) , and the extracts were combined, dried over MgS0 4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound. 5-methyl-2 ' -deoxycytidine (5-me-C) containing oligonucleotides were synthesized according to published methods (Sanghvi et al . , Nucl . Acids Res . 1993, 21 , 3197- 3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) . Oligonucleotides having methylene (methylimino) (MMI) backbones were synthesized according to U.S. Patent 5,378,825, which is coassigned to the assignee of the present invention and is incorporated herein in its entirety. For ease of synthesis, various nucleoside dimers containing MMI linkages were synthesized and incorporated into oligonucleotides. Other nitrogen-containing backbones are synthesized according to WO 92/20823 which is also coassigned to the assignee of the present invention and incorporated herein in its entirety. Oligonucleotides having amide backbones are synthesized according to De Mesmaeker et al . {Ace . Chem. Res . 1995, 28, 366-374) . The amide moiety is readily accessible by simple and well-known synthetic methods and is compatible with the conditions required for solid phase synthesis of oligonucleotides. Oligonucleotides with morpholino backbones are synthesized according to U.S. Patent 5,034,506 (Summerton and Weller) . Peptide-nucleic acid (PNA) oligomers are synthesized according to P.E. Nielsen et al . { Science 1991, 254 , 1497- 1500) . After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol . Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by 31 P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al . {J. Biol . Chem. 1991, 266, 18162) . Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material . EXAMPLE 2: Human TNF-α Oligodeoxynucleotide Sequences Antisense oligonucleotides were designed to target human TNF-α. Target sequence data are from the TNF-α cDNA sequence published by Nedwin,G.E. et al . {Nucleic Acids Res . 1985, 13 , 6361-6373); Genbank accession number X02910, provided herein as SEQ ID NO: 1. Oligodeoxynucleotides were synthesized primarily with phosphorothioate linkages. Oligonucleotide sequences are shown in Table 1. Oligonucleotide 14640 (SEQ ID NO. 2) is a published TNF-α antisense oligodeoxynucleotide targeted to the start site of the TNF-α gene (Hartmann, G. , et al . , Antisense Nucleic Acid Drug Dev. , 1996, 6, 291-299). Oligonucleotide 2302 (SEQ ID NO. 41) is an antisense oligodeoxynucleotide targeted to the human intracellular adhesion molecule-1 (ICAM-1) and was used as an unrelated (negative) target control. Oligonucleotide 13664 (SEQ ID NO. 42) is an antisense oligodeoxynucleotide targeted to the Herpes Simplex Virus type 1 and was used as an unrelated target control . NeoHK cells, human neonatal foreskin keratinocytes (obtained from Cascade Biologicals, Inc., Portland, OR) were cultured in Keratinocyte medium containing the supplied growth factors (Life Technologies, Rockville, MD) . At assay time, the cells were between 70% and 90% confluent. The cells were incubated in the presence of Keratinocyte medium, without the supplied growth factors added, and the oligonucleotide formulated in LIPOFECTIN ® (Life Technologies), a 1:1 (w/w) liposome formulation of the cationic lipid N- [1- (2 , 3-dioleyloxy)propyl] -n,n,n- trimethylammonium chloride (DOTMA) , and dioleoyl phosphotidylethanolamine (DOPE) in membrane filtered water. For an initial screen, the oligonucleotide concentration was 300 nM in 9 μg/mL LIPOFECTIN ® . Treatment was for four hours. After treatment, the medium was removed and the cells were further incubated in Keratinocyte medium containing the supplied growth factors and 100 nM phorbol 12-myristate 13-acetate (PMA, Sigma, St. Louis, MO). mRNA was analyzed 2 hours post-induction with PMA. Protein levels were analyzed 12 to 20 hours post-induction. Total mRNA was isolated using the RNEASY ® Mini Kit (Qiagen, Valencia, CA; similar kits from other manufacturers may also be used) , separated on a 1% agarose gel, transferred to HYBOND™-N+ membrane (Amersham Pharmacia Biotech, Piscataway, NJ) , a positively charged nylon membrane, and probed. A TNF-α probe consisted of the 505 bp EcoRI-Hindlll fragment from BBG 18 (R&D Systems, Minneapolis, MN) , a plasmid containing human TNF-α cDNA. A glyceraldehyde 3-phosphate dehydrogenase (G3PDH) probe consisted of the 1.06 kb Hindlll fragment from pHcGAP (American Type Culture Collection, Manassas, VA) , a plasmid containing human G3PDH cDNA. The restriction fragments were purified from low-melting temperature agarose, as described in Maniatis, T., et al . , Molecular Cloning: A Laboratory Manual , 1989 and labeled with REDIVUE™ 32 P-dCTP (Amersham Pharmacia Biotech, Piscataway, NJ) and PRIME-A- GENE ® labeling kit (Promega, Madison, WI) . mRNA was quantitated by a Phospholmager (Molecular Dynamics, Sunnyvale, CA) . Secreted TNF-α protein levels were measured using a human TNF-α ELISA kit (R&D Systems, Minneapolis, MN or Genzyme, Cambridge, MA) . TABLE 1 Nucleotide Sequences of Human TNF-α Phosphorothioate Oligodeoxynucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5 1 -> 3') NO: CO-ORDINATES 2 REGION 14640 CATGCTTTCAGTGCT£AT 2 0796- -0813 AUG 14641 TGAGGGAGCGTCTGCTGGCT 3 0615- -0634 5 ' -UTR 14642 GTGCTCATGGTGT£CTTT£C_ 4 0784- -0803 AUG 14643 TAATCACAAGTGCAAACATA 5 3038- -3057 3 ■ -UTR 14644 TAC£C£GGTCT££CAAATAA 6 3101- -3120 3 ' -UTR 14810 GTGCTCATGGTGTCCTTTCC 4 0784--0803 AUG 14811 AGCACCGCCTGGAGCCCT 7 0869- -0886 coding 14812 GCTGAGGAACAAGCACCGCC 8 0878- -0897 coding 14813 AGGCAGAAGAGCGTGGTGGC 9 0925- -0944 coding 14814 AAAGTGCAGCAGGCAGAAGA 10 0935- -0954 coding 14815 TTAGAGAGAGGTCCCTGG 11 1593- -1610 coding 14816 TGACTGCCTGGGCCAGAG 12 1617- -1634 junction 14817 GGGTTCGAGAAGATGATC 13 1822- -1839 junction 14818 GGGCTACAGGCTTGTCACTC 14 1841- -1860 coding 14820 CCCCTCAGCTTGAGGGTTTG 15 2171- -2190 junction 14821 CCATTGGCCAGGAGGGCATT 16 2218- -2237 coding 14822 ACCACCAGCTGGTTATCTCT 17 2248- -2267 coding 14823 CTGGGAGTAGATGAGGTACA 18 2282- -2301 coding 14824 CCCTTGAAGAGGACCTGGGA 19 2296- -2315 coding 14825 GGTGTGGGTGAGGAGCACAT 20 2336- -2355 coding 14826 GTCTGGTAGGAGACGGCGAT 21 2365- -2384 coding 14827 GCAGAGAGGAGGTTGACCTT 22 2386- -2405 coding 14828 GCTTGGCCTCAGCCCCCTCT 23 2436- -2455 coding 14829 CCTCCCAGATAGATGGGCTC 24 2464-2483 coding 14830 CCCTTCTCCAGCTGGAAGAC 25 2485-2504 coding 14831 ATCTCAGCGCTGAGTCGGTC 26 2506-2525 coding 14832 TCGAGATAGTCGGGCCGATT 27 2527-2546 coding 14833 AAGTAGACCTGCCCAGACTC 28 2554-2573 coding 14834 GGATGTTCGTCCTCCTCACA 29 2588-2607 STOP 14835 ACCCTAAGCCCCCAATTCTC 30 2689-2708 3 -UTR 14836 CCACACATTCCTGAATCCCA 31 2758-2777 3 -UTR 14837 AGGCCCCAGTGAGTTCTGGA 32 2825-2844 3 -UTR 14838 GTCTCCAGATTCCAGATGTC 33 2860-2879 3 -UTR 14839 CTCAAGTCCTGCAGCATTCT 34 2902-2921 3 -UTR 14840 TGGGTCCCCCAGGATACCCC 35 3115-3134 3 -UTR 14841 ACGGAAAACATGTCTGAGCC 36 3151-3170 3 -UTR 14842 CTCCGTTTTCACGGAAAACA 37 3161-3180 3 -UTR 14843 GCCTATTGTTCAGCTCCGTT 38 3174-3193 3 -UTR 14844 GGTCACCAAATCAGCATTGT 39 3272-3292 3 -UTR 14845 GAGGCTCAGCAATGAGTGAC 40 3297-3316 3 -UTR 2302 G£C£AAG£TGG£AT£CGT£A 41 target control 13664 GCCGAGGTCCATGTCGTACGC 42 target control 1 "C" residues are 5-methyl-cytosines except "C" residues are unmodified cytidines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. Results are shown in Table 2. Oligonucleotides 14828 (SEQ ID NO. 23), 14829 (SEQ ID NO. 24), 14832 (SEQ ID NO. 27), 14833 (SEQ ID NO. 28), 14834 (SEQ ID NO. 29), 14835 (SEQ ID NO. 30), 14836 (SEQ ID NO. 31), 14839 (SEQ ID NO. 34), 14840 (SEQ ID NO. 35), and 14844 (SEQ ID NO. 39) inhibited TNF-α expression by approximately 50% or more. Oligonucleotides 14828 (SEQ ID NO. 23), 14834 (SEQ ID NO. 29) , and 14840 (SEQ ID NO. 35) gave better than 70% inhibition. TABLE 2 Inhibition of Human TNF-α mRNA Expression by Phosphorothioate 01igodeoxynucleotides ISIS SEQ GENE % mRNA % mRNA No: ID TARGET EXPRESSION INHIBITION NO: REGION basal 16% induced 100% 0% 13664 42 control 140% 14640 2 AUG 61% 39% 14641 3 5' -UTR 95% 5% 14642 4 AUG 131% 14810 4 AUG 111% 14815 11 coding 85% 15% 14816 12 junction 106% 14817 13 junction 97% 3% 14818 14 coding 64% 36% 14820 15 junction 111% 14821 16 coding 91% 9% 14822 17 coding 57% 43% 14827 22 coding 67% 33% 14828 23 coding 27% 73% 14829 24 coding 33% 67% 14830 25 coding 71% 29% 14831 26 coding 62% 38% 14832 27 coding 40% 60% 14833 28 coding 43% 57% 14834 29 STOP 26% 74% 14835 30 3' -UTR 32% 68% 14836 31 3 '-UTR 40% 60% 14837 32 3 ' -UTR 106% 14838 33 3 ' -UTR 70% 30% 14839 34 5' -UTR 49% 51% 14840 35 3 ■ -UTR 28% 72% 14841 36 3 ' -UTR 60% 40% 14842 37 3 ' -UTR 164% 14843 38 3 ' -UTR 67% 33% 14844 39 3 ' -UTR 46% 54% 14845 40 3 ■ -UTR 65% 35% EXAMPLE 3: Dose response of antisense phosphorothioate oligodeoxynucleotide effects on human TNF-α mRNA levels in NeoHK cells Four of the more active oligonucleotides from the initial screen were chosen for dose response assays . These include oligonucleotides 14828 (SEQ ID NO. 23), 14833 (SEQ ID NO. 28), 14834 (SEQ ID NO. 29) and 14839 (SEQ ID NO. 34) . NeoHK cells were grown, treated and processed as described in Example 2. LIPOFECTIN ® was added at a ratio of 3 μg/mL per 100 nM of oligonucleotide. The control included LIPOFECTIN ® at a concentration of 9 μg/mL. The effect of the TNF-α antisense oligonucleotides was normalized to the non-specific target control. Results are shown in Table 3. Each oligonucleotide showed a dose response effect with maximal inhibition greater than 70%. Oligonucleotides 14828 (SEQ ID NO. 23) had an IC 50 of approximately 185 nM. Oligonucleotides 14833 (SEQ ID NO. 28) had an IC 50 of approximately 150 nM. Oligonucleotides 14834 (SEQ ID NO. 29) and 14839 (SEQ ID NO. 34) had an IC 50 of approximately 140 nM. TABLE 3 Dose Response of NeoHK Cells to TNF-α Antisense Phosphorothioate Oligodeoxynucleotides (ASOs) SEQ ASO Gene % mRNA % mRNA ISIS # ID Target Dose Expression Inhibition NO: 2302 41 control 25 nM 100% II II II 50 nM 100% II II II 100 nM 100% II II II 200 nM 100% II II II 300 nM 100% 14828 23 coding 25 nM 122% II II II 50 nM 97% 3% II II II 100 nM 96% 4% II II II 200 nM 40% 60% II II II 300 nM 22% 78% 14833 28 coding 25 nM 89% 11% II II II 50 nM 78% 22% II II II 100 nM 64% 36% II II II 200 nM 36% 64% II II II 300 nM 25% 75% 14834 29 STOP 25 nM 94% 6% II II II 50 nM 69% 31% II II II 100 nM 65% 35% II II II 200 nM 26% 74% II II II 300 nM 11% 89% 14839 34 3 '-UTR 25 nM 140% II II II 50 nM 112% II II II 100 nM 65% 35% II II II 200 nM 29% 71% II II II 300 nM 22% 78% EXAMPLE 4 : Design and Testing of Chimeric (deoxy gapped) 2 • -O- methoxyethyl TNF-α Antisense Oligonucleotides on TNF-α Levels in NeoHK Cells Oligonucleotides having SEQ ID NO: 28 and SEQ ID NO: 29 were synthesized as uniformly phosphorothioate or mixed phosphorothioate/phosphodiester chimeric oligonucleotides having variable regions of 2 ' -O-methoxyethyl (2'-MOE) nucleotides and deoxynucleotides. The sequences and the oligonucleotide chemistries are shown in Table 4. All 2 ' -MOE cytosines were 5-methyl-cytosines . Dose response experiments, as discussed in Example 3, were performed using these chimeric oligonucleotides. The effect of the TNF-α antisense oligonucleotides was normalized to the non-specific target control. Results are shown in Table 5. The activities of the chimeric oligonucleotides tested were comparable to the parent phosphorothioate oligonucleotide . TABLE 4 Nucleotide Sequences of TNF-α Chimeric (deoxy gapped) 2 • -O-methoxyethyl Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE ID NUCLEOTIDE TARGET NO. (5- -> 3') NO: CO-ORDINATES 1 REGION 14833 AsAsGsTsAsGsAsCsCsTsGsCsCsCsAsGsAsCsTsC 28 2554-2573 coding 16467 AoAoGoToAsGsAsCsCsTsGsCsCsCsAsGoAoCoToC 28 2554-2573 coding 16468 AsAsGsTsAsGsAsCsCsTsGsCsCsCsAsGsAsCsTsC 28 2554-2573 coding 16469 AsAsGsTsAsGsAsCsCsTsGsCsCsCsAsGsAsCsTsC 28 2554-2573 coding 16470 AsAsGsTsAsGsAsCsCsTsGsCsCsCsAsGsAsCsTsC 28 2554-2573 coding 16471 AsAsGsTsAsGsAsCsCsTsGsCsCsCsAsGsAsCsTsC 28 2554-2573 coding 14834 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 16472 GoGoAoToGsTsTsCsGsTsCsCsTsCsCsToCoAoCoA 29 2588-2607 STOP 16473 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 16474 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 16475 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 16476 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 1 Emboldened residues are 2 ■ -methoxyethoxy residues (others are 2 '-deoxy-). All 2 ' -methoxyethoxy cytidines are 5-methyl-cytidines; "s" linkages are phosphorothioate linkages, "o" linkages are phosphodiester linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1 TABLE 5 Dose Response of NeoHK Cells to TNF-α Chimeric (deoxy gapped) 2 ' -O-methoxyethyl Antisense Oligonucleotides SEQ ASO Gene % mRNA % mRNA ISIS # I IDD T Taarrggeett D Doossee Expression Inhibition N NOO:: 13664 4 422 ccoonnttrrooll 5 500 nnMM 100% II II 1 10000 nnMM 100% II II 2 20000 nnMM 100% M II 3 30000 nnMM 100% 14833 2 288 ccooddminqg 5 500 nnMM 69% 31% II II 1 10000 nnMM 64% 36% II II 2 20000 nnMM 56% 44% II II 3 30000 nnMM 36% 64% 16468 2 288 ccooddiinngg 5 500 nnMM 66% 34% II II 1 10000 nnMM 53% 47% II II 2 20000 nnMM 34% 66% II II 3 30000 nnMM 25% 75% 16471 2 288 ccooddiinngg 5 500 nnMM 77% 23% II II 1 10000 nnMM 56% 44% II II 2 20000 nnMM 53% 47% II II 3 30000 nnMM 31% 69% 14834 2 299 S STTOOPP 5 500 nnMM 74% 26% II II 1 10000 nnMM 53% 47% II II 2 20000 nnMM 24% 76% II II 3 30000 nnMM 11% 89% 16473 2 299 S STTOOPP 5 500 nnMM 71% 29% II II 1 10000 nnMM 51% 49% II " 2 20000 nnMM 28% 72% II II 3 30000 nnMM 23% 77% 16476 2 299 S STTOOPP 5 500 nnMM 74% 26% 100 nM 58% 42% 200 nM 32% 68% 300 nM 31% 69% EXAMPLE 5: Design and Testing of Chimeric Phosphorothioate/MMI TNF-α Antisense Oligodeoxynucleotides on TNF-α Levels in NeoHK Cells Oligonucleotides having SEQ ID NO . 29 were synthesized as mixed phosphorothioate/methylene (methylimino) (MMI) chimeric oligodeoxynucleotides. The sequences and the oligonucleotide chemistries are shown in Table 6. Oligonucleotide 13393 (SEQ ID NO. 49) is an antisense oligonucleotide targeted to the human intracellular adhesion molecule-1 (ICAM-1) and was used as an unrelated target control. All cytosines were 5-methyl-cytosines . Dose response experiments were performed using these chimeric oligonucleotides, as discussed in Example 3 except quantitation of TNF-α mRNA levels was determined by real-time PCR (RT-PCR) using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in RT-PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, PE-Applied Biosystems, Foster City, CA) is attached to the 5 ' end of the probe and a quencher dye (e.g., TAMRA, PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5 ' -exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples. RT-PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μl PCR cocktail (lx TAQMAN ® buffer A, 5.5 mM MgCl 2 , 300 μM each of dATP, dCTP and dGTP, 600 μM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 U RNAse inhibitor, 1.25 units AMPLITAQ GOLD ® , and 12.5 U MuLV reverse transcriptase) to 96 well plates containing 25 μl poly (A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD ® , 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). For TNF-α the PCR primers were: Forward: 5 * -CAGGCGGTGCTTGTTCCT-3 ' SEQ ID NO. 43 Reverse: 5 ' -GCCAGAGGGCTGATTAGAGAGA-3 ' SEQ ID NO. 44 and the PCR probe was: FAM-CTTCTCCTTCCTGATCGTGGCAGGC-TAMRA (SEQ ID NO. 45) where FAM or JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For GAPDH the PCR primers were: Forward primer: 5 ' -GAAGGTGAAGGTCGGAGTC-3 ' SEQ ID NO. 46 Reverse primer: 5 ' -GAAGATGGTGATGGGATTTC-3 ' SEQ ID NO. 47 and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC - TAMRA 3' (SEQ ID NO. 48) where FAM or JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye . Results are shown in Table 7. The oligonucleotide containing MMI linkages was more effective in reducing TNF- α mRNA levels than the uniformly phosphorothioate oligonucleotide. The IC 50 value was reduced from approximately 75 nM, for oligonucleotide 14834 (SEQ ID NO: 29) , to approximately 30 nM for oligonucleotide 16922 (SEQ ID NO: 29) . Dose response experiments were also performed measuring the effect on TNF-α protein levels. Protein levels were measured as described in Example 2. Results are shown in Table 8. The oligonucleotide containing four MMI linkages on each end was more effective in reducing protein levels than the uniformly phosphorothioate oligonucleotide. The IC 50 value was reduced from approximately 90 nM, for oligonucleotide 14834 (SEQ ID NO: 29) , to approximately 45 nM for oligonucleotide 16922 (SEQ ID NO: 29) . TABLE 6 Nucleotide Sequences of Human TNF-α Chimeric Phosphorothioate/MMI Oligodeoxynucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 1 REGION 14834 GsGsAsTsGsTsTsCsGsTsCsCsTsCsCsTsCsAsCsA 29 2588-2607 STOP 16922 GmGmAmTmGsTsTsCsGsTsCsCsTsCsCsTmCmAmCmA 29 2588-2607 STOP 16923 GmGmAmTmGmTmTsCsGsTsCsCsTsCmCmTmCmAmCmA 29 2588-2607 STOP I 13393 TsCsTsGsAsGsTsAsGsCsAsGsAsGsGsAsGsCsTsC 49 target control 1 All cytosine residues are 5-methyl-cytosines; "s" linkages are phosphorothioate linkages, "m" linkages are methylene (methylimino) (MMI). 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1 TABLE 7 Dose Response of Chimeric Phosphorothioate/MMI TNF-α Antisense Oligodeoxynucleotides on TNF-α mRNA Levels in PMA-Induced NeoHK Cells SEQ ASO Gene % mRNA % mRNA ISIS # ID Target Dose Expression Inhibition NO: induced 100% 13393 49 control 25 nM 87.3% 12.7% 50 nM 98.5% 1.5% 100 nM 133.1% 200 nM 139.6% 14834 29 STOP 25 nM 98.7% 1.3% 50 nM 70.8% 29.2% 100 nM 36.0% 64.0% 200 nM 38.2% 61.8% 16922 29 STOP 25 nM 58.9% 41.1% 50 nM 28.2% 71.8% 100 nM 22.2% 77.8% 200 nM 18.9% 81.1% TABLE 8 Dose Response of Chimeric Phosphorothioate/MMI TNF-α Antisense Oligodeoxynucleotides on TNF-α Protein Levels in PMA-Induced NeoHK Cells SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 100.0% 13393 49 control 25 nM 117.0% II II II 50 nM 86.6% 13.4% 100 nM 98.7% 1.3% 200 nM 78.0% 22.0% 14834 29 STOP 25 nM 84.8% 15.2% 50 nM 76.9% 23.1% 100 nM 44.5% 55.5% 200 nM 18.7% 81.3% 16922 29 STOP 25 nM 67.1% 32.9% 50 nM 48.6% 51.4% 100 nM 20.0% 80.0% 200 nM 7.9% 92.1% 16923 29 STOP 25 nM 79.9% 20.1% 50 nM 69.9% 30.1% 100 nM 56.0% 44.0% 200 nM 44.5% 55.5% EXAMPLE 6: Additional Human TNF-α Antisense Oligonucleotide Sequences A second screening of human TNF-α antisense oligonucleotides was performed. Oligonucleotides were designed specifically against specific regions of the TNF-α gene. A series of oligonucleotides was designed to target introns 1 and 3, and exon 4. Sequences targeting introns 1 or 3 were synthesized as uniformly phosphorothioate oligodeoxynucleotides or mixed phosphorothioate/ phosphodiester chimeric backbone oligonucleotides having variable regions of 2 ' -O-methoxyethyl (2'-MOE) nucleotides and deoxynucleotides. Sequences targeting exon 4 were synthesized as mixed phosphorothioate/phosphodiester chimeric backbone oligonucleotides having variable regions of 2 ' -O-methoxyethyl (2'-M0E) nucleotides and deoxynucleotides. The sequences of the chimeric oligonucleotides are shown in Table 9. Sequences of the uniformly phosphorothioate oligodeoxynucleotides are shown in Table 11. These oligonucleotides were screened at 50 nM and 200 nM for their ability to inhibit TNF-α protein secretion, essentially as described in Example 2. Results for the chimeric backbone oligonucleotides are shown in Table 10; results for the uniformly phosphorothioate oligodeoxynucleotides are shown in Table 12. For the chimeric backbone oligonucleotides targeting introns 1 or 3 , oligonucleotide 21688 (SED ID NO. 69) gave 60% inhibition or greater. For chimeric backbone oligonucleotides targeting exon 4, two-thirds of the oligonucleotides gave nearly 60% inhibition or greater (SEQ ID NOs. 88, 90, 91, 92, 93, 94, 97, and 98). See Table 10. For the uniformly phosphorothioate oligodeoxynucleotides, five of nine oligonucleotides targeting intron 3 were effective in reducing TNF-α expression by nearly 60% or greater (SEQ ID NOs. 79, 80, 81, 82, and 84) . See Table 12. Oligonucleotides having SEQ ID NO. 91 and SEQ ID NO. 98 were synthesized as a uniformly phosphorothioate oligodeoxynucleotides or mixed phosphorothioate/ phosphodiester chimeric backbone oligonucleotides having variable regions of 2 ' -O-methoxyethyl (2'-MOE) nucleotides and deoxynucleotides. The sequences and the oligonucleotide chemistries are shown in Table 13. All 2 ' - MOE cytosines and 2 '-deoxy cytosines were 5-methyl- cytosines. Dose response experiments, as discussed in Example 3, were performed using these oligonucleotides. Included in this experiment were two oligonucleotides targeting intron 1 and two oligonucleotides targeting intron 3. Results are shown in Tables 14 and 15. The oligonucleotides targeting exon 4 with variable regions of 2 ' -O-methoxyethyl (2' -MOE) nucleotides and deoxynucleotides and/or uniformly phosphorothioate or mixed phosphorothioate/phosphodiester were, in general, comparable to the parent compound. Oligonucleotides targeting introns 1 or 3 having SEQ ID NOs 66, 69 and 80 were effective in reducing TNF-α mRNA levels by greater than 80% and showed a dose response effect with an IC S0 approximately 110 nM. See Tables 14 and 15. TABLE 9 Nucleotide Sequences of TNF-α Chimeric Backbone (deoxy gapped) 2 ' -O-methoxyethyl Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE ID NUCLEOTIDE TARGET NO. (5' -> 3") NO: CO-ORDINATES 1 REGION 21669 ToGoCoGoTsCsTsCsTsCsAsTsTsTsCsCoCoCoToT 50 1019-1038 intron 1 21670 ToCoCoCoAsTsCsTsCsTsCsTsCsCsCsToCoToCoT 51 1039-1058 intron 1 21671 CoAoGoCoGsCsAsCsAsTsCsTsTsTsCsAoCoCoCoA 52 1059-1078 intron 1 1 21672 ToCoToCoTsCsTsCsAsTsCsCsCsTsCsCoCoToAoT 53 1079-1098 intron 1 en 21673 CoGoToCoTsTsTsCsTsCsCsAsTsGsTsToToToToT 54 1099-1118 intron 1 1 21674 CoAoCoAoTsCsTsCsTsTsTsCsTsGsCsAoToCoCoC 55 1119-1138 intron 1 21675 CoToCoToCsTsTsCsCsCsCsAsTsCsTsCoToToGoC 56 1139-1158 intron 1 21676 GoToCoToCsTsCsCsAsTsCsTsTsTsCsCoToToCoT 57 1159-1178 intron 1 21677 ToToCoCoAsTsGsTsGsCsCsAsGsAsCsAoToCoCoT 58 1179-1198 intron 1 21678 AoToAoCoAsCsAsCsTsTsAsGsTsGsAsGoCoAoCoC 59 1199-1218 intron 1 21679 ToToCoAoTsTsCsAsTsTsCsAsTsTsCsAoCoToCoC 60 1219-1238 intron 1 21680 ToAoToAoTsCsTsGsCsTsTsGsTsTsCsAoToToCoA 61 1239-1258 intron 1 21681 CoToGoToCsTsCsCsAsTsAsTsCsTsTsAoToToToA 62 1259-1278 intron 1 21682 ToCoToCoTsTsCsTsCsAsCsAsCsCsCsCoAoCoAoT 63 1279-1298 intron 1 21683 CoAoCoToTsGsTsTsTsCsTsTsCsCsCsCoCoAoToC 64 1299-1318 intron 1 21684 CoToCoAoCsCsAsTsCsTsTsTsAsTsTsCoAoToAoT 65 1319-1338 intron 1 21685 AoToAoToTsTsCsCsCsGsCsTsCsTsTsToCoToGoT 66 1339-1358 intron 1 21686 CoAoToCoTsCsTsCsTsCsCsTsTsAsGsCoToGoToC 67 1359-1378 intron 1 21687 ToCoToToCsTsCsTsCsCsTsTsAsTsCsToCoCoCoC 68 1379-1398 intron 1 21688 GoToGoToGsCsCsAsGsAsCsAsCsCsCsToAoToCoT 69 1399-1418 intron 1 21689 ToCoToToTsCsCsCsTsGsAsGsTsGsTsCoToToCoT 70 1419-1438 intron 1 21690 AoCoCoToTsCsCsAsGsCsAsTsTsCsAsAoCoAoGoC 71 1439-1458 intron 1 21691 CoToCoCoAsTsTsCsAsTsCsTsGsTsGsToAoToToC 72 1459-1478 intron 1 21692 ToGoAoGoGsTsGsTsCsTsGsGsTsTsTsToCoToCoT 73 1479-1498 intron 1 21693 AoCoAoCoAsTsCsCsTsCsAsGsAsGsCsToCoToToA 74 1871-1890 intron 3 21694 CoToAoGoCsCsCsTsCsCsAsAsGsTsTsCoCoAoAoG 75 1891-1910 intron 3 21695 CoGoGoGoCsTsTsCsAsAsTsCsCsCsCsAoAoAoToC 76 1911-1930 intron 3 21696 AoAoGoToTsCsTsGsCsCsTsAsCsCsAsToCoAoGoC 77 1931-1950 intron 3 21697 GoToCoCoTsTsCsTsCsAsCsAsTsTsGsToCoToCoC 78 1951-1970 intron 3 21698 CoCoToToCsCsCsTsTsGsAsGsCsTsCsAoGoCoGoA 79 1971-1990 intron 3 21699 GoGoCoCoTsGsTsGsCsTsGsTsTsCsCsToCoCoAoC 80 1991-2010 intron 3 21700 CoGoToToCsTsGsAsGsTsAsTsCsCsCsAoCoToAoA 81 2011- 2030 intron 3 21701 CoAoCoAoTsCsCsCsAsCsCsTsGsGsCsCoAoToGoA 82 2031- 2050 intron 3 21702 GoToCoCoTsCsTsCsTsGsTsCsTsGsTsCoAoToCoC 83 2051- 2070 intron 3 21703 CoCoAoCoCsCsCsAsCsAsTsCsCsGsGsToToCoCoT 84 2071- 2090 intron 3 21704 ToCoCoToGsGsCsCsCsTsCsGsAsGsCsToCoToGoC 85 2091- 2110 intron 3 21705 AoToGoToCsGsGsTsTsCsAsCsTsCsTsCoCoAoCoA 86 2111- 2130 intron 3 21706 AoGoAoGoGsAsGsAsGsTsCsAsGsTsGsToGoGoCoC 87 2131- 2150 intron 3 21722 GoAoToCoCsCsAsAsAsGsTsAsGsAsCsCoToGoCoC 88 2561- 2580 exon 4 21723 CoAoGoAoCsTsCsGsGsCsAsAsAsGsTsCoGoAoGoA 89 2541- 2560 exon 4 o 21724 ToAoGoToCsGsGsGsCsCsGsAsTsTsGsAoToCoToC 90 2521- 2540 exon 4 21725 AoGoCoGoCsTsGsAsGsTsCsGsGsTsCsAoCoCoCoT 91 2501- 2520 exon 4 21726 ToCoToCoCsAsGsCsTsGsGsAsAsGsAsCoCoCoCoT 92 2481- 2500 exon 4 21727 CoCoCoAoGsAsTsAsGsAsTsGsGsGsCsToCoAoToA 93 2461- 2480 exon 4 21728 CoCoAoGoGsGsCsTsTsGsGsCsCsTsCsAoGoCoCoC 94 2441- 2460 exon 4 21729 CoCoToCoTsGsGsGsGsTsCsTsCsCsCsToCoToGoG 95 2421- 2440 exon 4 21730 CoAoGoGoGsGsCsTsCsTsTsGsAsTsGsGoCoAoGoA 96 2401- 2420 exon 4 21731 GoAoGoGoAsGsGsTsTsGsAsCsCsTsTsGoGoToCoT 7 2381-2400 exon 4 21732 GoGoToAoGsGsAsGsAsCsGsGsCsGsAsToGoCoGoG 8 2361-2380 exon 4 21733 CoToGoAoTsGsGsTsGsTsGsGsGsTsGsAoGoGoAoG 9 2341-2360 exon 4 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2'- methoxyethoxy cytidines and 2 ' -deoxycytidines are 5-methyl-cytidines; "s" linkages are phosphorothioate linkages, "o" linkages are phosphodiester linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1 o TABLE 10 Dose Response of PMA-Induced neoHK Cells to Chimeric Backbone (deoxy gapped) 2 ' -O-methoxyethyl TNF-α Antisense Oligonucleotides SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO! induced 100% 14834 29 STOP 50 nM 76% 24% II II II 200 nM 16% 84% 21669 50 intron 1 50 nM 134% II II II 200 nM 114% 21670 51 intron 1 50 nM 122% II II II 200 nM 101% 21671 52 intron 1 50 nM 90% 10% II " II 200 nM 58% 42% 21672 53 intron 1 50 nM 122% II II II 200 nM 131% 21673 54 intron 1 50 nM 102% II II 200 nM 110% 21674 55 intron 1 50 nM 111% II II 200 nM 96% 4% 21675 56 intron 1 50 nM 114% II II 200 nM 99% 21676 57 intron 1 50 nM 107% II II 200 nM 96% 4% 21677 58 intron 1 50 nM 86% 14% II II 200 nM 95% 5% 21678 59 intron 1 50 nM 106% II II 200 nM 107% 21679 60 intron 1 50 nM 75% 25* II II 200 nM 73% 27 ! 21680 61 intron 1 50 nM 76% 24% II 200 nM 80% 20% 21681 62 intron 1 50 nM 79% 21% II 200 nM 82% 18% 21682 63 intron 1 50 nM 102% II 200 nM 88% 12% 21683 64 intron 1 50 nM 80% 20% II 200 nM 66% 34% 21684 65 intron 1 50 nM 91% 9% II 200 nM 69% 31% 21685 66 intron 1 50 nM 98% 2% II 200 nM 90% 10% 21686 67 intron 1 50 nM 97% 3% II 200 nM 72% 28% 21687 68 intron 1 50 nM 103% II 200 nM 64% 36% 21688 69 intron 1 50 nM 87% 13% II 200 nM 40% 60% 21689 70 intron 1 50 nM 78% 22% II II 200 nM 74% 26% 21690 71 intron 1 50 nM 84% 16% II II 200 nM 80% 20% 21691 72 intron 1 50 nM 86% 14% II II 200 nM 75% 25% 21692 73 intron 1 50 nM 85% 15% II 200 nM 61% 39% 21693 74 intron 3 50 nM 81% 19% II 200 nM 83% 17% 21694 75 intron 3 50 nM 99% 1% 200 nM 56% 44% 21695 76 intron 3 50 nM 87% 13% 200 nM 84% 16% 21696 77 intron 3 50 nM 1033 II 200 nM 86% 14% 21697 78 intron 3 50 nM 99% 1% II 200 nM 52% 48% 21698 79 intron 3 50 nM 96% 4% II 200 nM 47% 53% 21699 80 intron 3 50 nM 73% 27% II 200 nM 84% 16% 21700 81 intron 3 50 nM 80% 20% II 200 nM 53% 47% 21701 82 intron 3 50 nM 94% 6% II 200 nM 56% 44% 21702 83 intron 3 50 nM 86% 14% II 200 nM 97% 3% 21703 84 intron 3 50 nM 88% 12% II 200 nM 74% 26% 21704 85 intron 3 50 nM 69% 31% II 200 nM 65% 35% 21705 86 intron 3 50 nM 92% 8% II 200 nM 77% 23% 21706 87 intron 3 50 nM 95% 5% II 200 nM 82% 18% 21722 88 exon 4 50 nM 81% 19% II 200 nM 41% 59% 21723 89 exon 4 50 nM 87% 13% II 200 nM 74% 26% 21724 90 exon 4 50 nM 68% 32% II 200 nM 33% 67% 21725 91 exon 4 50 nM 55% 45% II 200 nM 30% 70% 21726 92 exon 4 50 nM 72% 28% II 200 nM 40% 60% 21727 93 exon 4 50 nM 67% 33% II 200 nM 40% 60% 21728 94 exon 4 50 nM 62% 38% II 200 nM 41% 59% 21729 95 exon 4 50 nM 78% 22% II 200 nM 53% 47% 21730 96 exon 4 50 nM 68% 32% II 200 nM 48% 52% 21731 97 exon 4 50 nM 77% 23% II 200 nM 41% 59% 21732 98 exon 4 50 nM 62% 38% II 200 nM 28% 72% 21733 99 exon 4 50 nM 92% 8% II 200 nM 74% 26% TABLE 11 Nucleotide Sequences of Additional Human TNF-α Phosphorothioate Oligodeoxynucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5" -> 3') NO: CO - ORDINATES 2 REGION 21804 TGCGTCTCTCATTTCCCCTT 50 1019- 1038 intron 1 21805 TCCCATCTCTCTCCCTCTCT 51 1039- 1058 intron 1 21806 CAGCGCACATCTTTCACCCA 52 1059- 1078 intron 1 21807 TCTCTCTCATCCCTCCCTAT 53 1079- 1098 intron 1 21808 CGTCTTTCTCCATGTTTTTT 54 1099- 1118 intron 1 21809 CACATCTCTTTCTGCATCCC 55 1119- 1138 intron 1 21810 CTCTCTTCCCCATCTCTTGC 56 1139- 1158 intron 1 21811 GTCTCTCCATCTTTCCTTCT 57 1159- 1178 intron 1 21812 TTCCATGTGCCAGACATCCT 58 1179- 1198 intron 1 21813 ATACACACTTAGTGAGCACC 59 1199- 1218 intron 1 21814 TTCATTCATTCATTCACTCC 60 1219- 1238 intron 1 21815 TATATCTGCTTGTTCATTCA 61 1239 -1258 intron 1 21816 CTGTCTCCATATCTTATTTA 62 1259- -1278 intron 1 21817 TCTCTTCTCACACCCCACAT 63 1279- -1298 intron 1 21818 CACTTGTTTCTTCCCCCATC 64 1299- -1318 intron 1 21819 CTCACCATCTTTATTCATAT 65 1319- -1338 intron 1 21820 ATATTTCCCGCTCTTTCTGT 66 1339- -1358 intron 1 21821 CATCTCTCTCCTTAGCTGTC 67 1359- -1378 intron 1 21822 TCTTCTCTCCTTATCTCCCC 68 1379- -1398 intron 1 21823 GTGTGCCAGACACCCTATCT 69 1399- -1418 intron 1 21824 TCTTTCCCTGAGTGTCTTCT 70 1419- -1438 intron 1 21825 ACCTTCCAGCATTCAACAGC 71 1439- -1458 intron 1 21826 CTCCATTCATCTGTGTATTC 72 1459- -1478 intron 1 21827 TGAGGTGTCTGGTTTTCTCT 73 1479- -1498 intron 1 21828 ACACATCCTCAGAGCTCTTA 74 1871- -1890 intron 3 21829 CTAGCCCTCCAAGTTCCAAG 75 1891- -1910 intron 3 21830 CGGGCTTCAATCCCCAAATC 76 1911- -1930 intron 3 21831 AAGTTCTGCCTACCATCAGC 77 1931- -1950 intron 3 21832 GTCCTTCTCACATTGTCTCC 78 1951- -1970 intron 3 21833 CCTTCCCTTGAGCTCAGCGA 79 1971- -1990 intron 3 21834 GGCCTGTGCTGTTCCTCCAC 80 1991- -2010 intron 3 21835 CGTTCTGAGTATCCCACTAA 81 2011- -2030 intron 3 21836 CACATCCCACCTGGCCATGA 82 2031- -2050 intron 3 21837 GTCCTCTCTGTCTGTCATCC 83 2051- -2070 intron 3 21838 CCACCCCACATCCGGTTCCT 84 2071- -2090 intron 3 21839 TCCTGGCCCTCGAGCTCTGC 85 2091- •2110 intron 3 21840 ATGTCGGTTCACTCTCCACA 86 2111- -2130 intron 3 21841 AGAGGAGAGTCAGTGTGGCC 87 2131- • 2150 intron 3 1 All "C" residues are 5-methyl-cytosines ; all linkages are phosphorothioate linkages . 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. TABLE 12 Dose Response of PMA-Induced neoHK Cells to TNF-α Antisense Phosphorothioate Oligodeoxynucleotides SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 100% 14834 29 STOP 50 nM 80% 20% 200 nM 13% 87% 21812 58 intron 1 50 nM 110% 200 nM 193% 21833 79 intron 3 50 nM 88% 12% 200 nM 8% 92% 21834 80 intron 3 50 nM 70% 30% 200 nM 18% 82% 21835 81 intron 3 50 nM 106% 200 nM 42% 58% 21836 82 intron 3 50 nM 71% 29% 200 nM 12% 88% 21837 83 intron 3 50 nM 129% 200 nM 74% 26% 21838 84 intron 3 50 nM 85% 15% 200 nM 41% 59% 21839 85 intron 3 50 nM 118% 200 nM 58% 42% 21840 86 intron 3 50 nM 120% 200 nM 96% 4% 21841 87 intron 3 50 nM 117% 200 nM 78% 22% TABLE 13 Nucleotide Sequences of TNF-α Chimeric (deoxy gapped) 2 ■ -O-methoxyethyl Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 1 REGION 21725 AoGoCoGoCsTsGsAsGsTsCsGsGsTsCsAoCoCoCoT 91 2501-2520 exon 4 25655 AsGsCsGsCsTsGsAsGsTsCsGsGsTsCsAsCsCsCsT 25656 AsGsCsGsCsTsGsAsGsTsCsGsGsTsCsAsCsCsCsT 25660 AoGoCoGsCsTsGsAsGsTsCsGsGsTsCsAsCoCoCoT e 21732 GoGoToAoGsGsAsGsAsCsGsGsCsGsAsToGoCoGoG 98 2361-2380 exon 4 25657 GsGsTsAsGsGsAsGsAsCsGsGsCsGsAsTsGsCsGsG 25658 GsGsTsAsGsGsAsGsAsCsGsGsCsGsAsTsGsCsGsG 25661 GoGoToAsGsGsAsGsAsCsGsGsCsGsAsTsGoCoGoG 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2'- methoxyethoxy cytidines and 2 ' -deoxycytidines are 5-methyl -cytidines; "s" linkages are phosphorothioate linkages, "o" linkages are phosphodiester linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. TABLE 14 Dose Response of 20 Hour PMA-Induced neoHK Cells to TNF-α Antisense Oligonucleotides (ASOs) SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 100% 14834 29 STOP 75 nM 91.2% 8.8% II 150 nM 42.0% 58.0% II 300 nM 16.9% 83.1% 21820 66 intron 1 75 nM 79.0% 21.0% II 150 nM 34.5% 65.5% II 300 nM 15.6% 84.4% 21823 69 intron 1 75 nM 79.5% 20.5% II 150 nM 31.8% 68.2% II 300 nM 16.2% 83.8% 21725 91 exon 4 75 nM 74.8% 25.2% II 150 nM 58.4% 41.6% II 300 nM 45.2% 54.8% 25655 91 exon 4 75 nM 112.0% II 150 nM 55.0% 45.0% II 300 nM 39.3% 60.7% 25656 91 exon 4 75 nM 108.3% II 150 nM 60.7% 39.3% " 300 nM 42.8% 57.2% 25660 91 exon 4 75 nM 93.2% 6.8% II 150 nM 72.8% 27.2% II 300 nM 50.3% 49.7% TABLE 15 Dose Response of 20 Hour PMA-Induced neoHK Cells to TNF-α Antisense Oligonucleotides (ASOs) SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 1 10000%% 14834 29 S STTOOPP 7 755 nnMM 4 444..99%% 5 555..11%% II 150 nM 16.3% 83.7% II 300 nM 2.2% 97.8% 21834 80 intron 3 75 nM 102.9% II 150 nM 24.5% 75.5% II 300 nM 19.1% 80.9% 21836 82 intron 3 75 nM 70.8% 29.2% II 150 nM 55.9% 44.1% II 300 nM 32.7% 67.3% 21732 98 exon 4 75 nM 42.4% 57.6% II 150 nM 34.9% 65.1% II 300 nM 15.4% 84.6% 25657 98 exon 4 75 nM 46.7% 53.3% II 150 nM 72.0% 28.0% II 300 nM 50.6% 49.4% 25658 98 exon 4 75 nM 83.7% 16.3% II 150 nM 56.6% 43.4% II 300 nM 36.9% 63.1% 25661 98 exon 4 75 nM 54.9% 45.1% II 150 nM 34.4% 65.6% II 300 nM 8.6% 91.4% EXAMPLE 7: Activity of Fully 2 ' -MOE Modified TNF-α Antisense Oligonucleotides A series of antisense oligonucleotides were synthesized targeting the terminal twenty nucleotides of each exon at every exon-intron junction of the TNF-α gene. These oligonucleotides were synthesized as fully 2 ' -methoxyethoxy modified oligonucleotides. The oligonucleotide sequences are shown in Table 16. Oligonucleotide 12345 (SEQ ID NO. 106) is an antisense oligonucleotide targeted to the human intracellular adhesion molecule-1 (ICAM-1) and was used as an unrelated target control . The oligonucleotides were screened at 50 nM and 200 nM for their ability to inhibit TNF-α mRNA levels, as described in Example 3. Results are shown in Table 17. Oligonucleotide 21794 (SEQ ID NO. 102) showed an effect at both doses, with greater than 75% inhibition at 200 nM. TABLE 16 Nucleotide Sequences of Human TNF-α Uniform 2 ' -MOE Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 2 REGION 3 21792 AGGCACTCACCTCTTCCCTC 100 0972-0991 El/11 21793 CCCTGGGGAACTGTTGGGGA 101 1579-1598 I1/E2 21794 AGACACTTACTGACTGCCTG 102 1625-1644 E2/I2 21795 GAAGATGATCCTGAAGAGGA 103 1812-1831 I2/E3 21796 GAGCTCTTACCTACAACATG 104 1860-1879 E3/I3 21797 TGAGGGTTTGCTGGAGGGAG 105 2161-2180 I3/E4 12345 GATCGCGTCGGACTATGAAG 106 target control 1 Emboldened residues are 2 ' -methoxyethoxy residues, 2'- methoxyethoxy cytosine residues are 5-methyl-cytosines ; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. 3 Each target region is an exon-intron junction and is represented in the form, for example, I1/E2, where I, followed by a number, refers to the intron number and E, followed by a number, refers to the exon number. TABLE 17 Dose Response of neoHK Cells to TNF-α Antisense 2 ' -MOE Oligonucleotides SEQ ASO Gene % mRNA % mRNA ISIS # ID Target Dose Expression Inhibition NO: induced 100% 12345 106 control 50 nM 121% II II II 200 nM 134% 13393 49 control 50 nM 110% II II II 200 nM 112% 14834 29 STOP 50 nM 92% 8% II II II 200 nM 17% 83% 21792 100 El/11 50 nM 105% II II II 200 nM 148% 21793 101 I1/E2 50 nM 106% II II II 200 nM 172% 21794 102 E2/I2 50 nM 75% 25% II II II 200 nM 23% 77% 21795 103 I2/E3 50 nM 79% 21% II II II 200 nM 125% 21796 104 E3/I3 50 nM 56% 44% II II II 200 nM 150% 21797 105 I3/E4 50 nM 90% 10% II II II 200 nM 128% EXAMPLE 8: Mouse TNF-α Oligonucleotide Sequences Antisense oligonucleotides were designed to target mouse TNF-α. Target sequence data are from the TNF- α cDNA sequence published by Semon,D. et al . {Nucleic Acids Res . 1987, 15, 9083-9084) ; Genbank accession number Y00467, provided herein as SEQ ID NO: 107. Oligonucleotides were synthesized primarily as phosphorothioate oligodeoxynucleotides. Oligonucleotide sequences are shown in Table 18. Oligonucleotide 3082 (SEQ ID NO. 141) is an antisense oligodeoxynucleotide targeted to the human intracellular adhesion molecule-1 (ICAM-1) and was used as an unrelated target control. Oligonucleotide 13108 (SEQ ID NO. 142) is an antisense oligodeoxynucleotide targeted to the herpes simplex virus type 1 and was used as an unrelated target control. P388D1, mouse macrophage cells (obtained from American Type Culture Collection, Manassas, VA) were cultured in RPMI 1640 medium with 15% fetal bovine serum (FBS) (Life Technologies, Rockville, MD) . At assay time, cell were at approximately 90% confluency. The cells were incubated in the presence of OPTI-MEM ® medium (Life Technologies, Rockville, MD) , and the oligonucleotide formulated in LIPOFECTIN ® (Life Technologies), a 1:1 (w/w) liposome formulation of the cationic lipid N- [1- (2, 3-dioleyloxy)propyl] -n,n,n- trimethylammonium chloride (DOTMA) , and dioleoyl phosphotidylethanolamine (DOPE) in membrane filtered water. For an initial screen, the oligonucleotide concentration was 100 nM in 3 μg/ml LIPOFECTIN ® . Treatment was for four hours. After treatment, the medium was removed and the cells were further incubated in RPMI medium with 15% FBS and induced with 10 ng/ml LPS . mRNA was analyzed 2 hours post-induction with PMA. Total mRNA was isolated using the TOTALLY RNA™ kit (Ambion, Austin, TX) , separated on a 1% agarose gel, transferred to HYBOND™-N+ membrane (Amersham, Arlington Heights, IL) , a positively charged nylon membrane, and probed. A TNF-α probe consisted of the 502 bp EcoRI- Hindlll fragment from BBG 56 (R&D Systems, Minneapolis, MN) , a plasmid containing mouse TNF-α cDNA. A glyceraldehyde 3 -phosphate dehydrogenase (G3PDH) probe consisted of the 1.06 kb HindiII fragment from pHcGAP (American Type Culture Collection, Manassas, VA) , a plasmid containing human G3PDH cDNA. The fragments were purified from low-melting temperature agarose, as described in Maniatis, T., et al . , Molecular Cloning: A Laboratory Manual , 1989 and labeled with REDIVUE™ 32 P-dCTP (Amersham Pharmacia Biotech, Piscataway, NJ) and PRIME-A-GENE ® labelling kit (Promega, Madison, WI) . mRNA was quantitated by a Phospholmager (Molecular Dynamics, Sunnyvale, CA) . Secreted TNF-α protein levels were measured using a mouse TNF-α ELISA kit (R&D Systems, Minneapolis, MN or Genzyme, Cambridge, MA) . TABLE 18 Nucleotide Sequences of Mouse TNF-α Phosphorothioate Oligodeoxynucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5 « -> 3') NO: CO-ORDINATES 2 REGION 14846 GAGCTTCTGCTGGCTGGCTG 108 4351-4370 5' -UTR 14847 CCTTGCTGTCCTCGCTGAGG 109 4371-4390 5 ' -UTR 14848 TCATGGTGTCTTTTCTGGAG 110 4511-4530 AUG 14849 CTTTCTGTGCTCATGGTGTC 111 4521-4540 AUG 14850 GCGGATCATGCTTTCTGTGC 112 4531-4550 coding 14851 GGGAGGCCATTTGGGAACTT 113 5225-5244 junction 14852 CGAATTTTGAGAAGATGATC 114 5457-5476 junction 14846 GAGCTTCTGCTGGCTGGCTG 108 4351 -4370 5 ' -UTR 14853 CTCCTCCACTTGGTGGTTTG 115 5799 -5818 junction 14854 CCTGAGATCTTATCCAGCCT 116 6540 -6559 3 ' -UTR 14855 CAATTACAGTCACGGCTCCC 117 6927 -6946 3 ' -UTR 15921 CCCTTCATTCTCAAGGCACA 118 5521 -5540 junction 15922 CACCCCTCAACCCGCCCCCC 119 5551 -5570 intron 15923 AGAGCTCTGTCTTTTCTCAG 120 5581 -5600 intron 15924 CACTGCTCTGACTCTCACGT 121 5611- -5630 intron 15925 ATGAGGTCCCGGGTGGCCCC 122 5651- -5670 intron 15926 CACCCTCTGTCTTTCCACAT 123 5681- -5700 intron 15927 CTCCACATCCTGAGCCTCAG 124 5731- -5750 intron 15928 ATTGAGTCAGTGTCACCCTC 125 5761- -5780 intron 15929 GCTGGCTCAGCCACTCCAGC 126 5821- -5840 coding 15930 TCTTTGAGATCCATGCCGTT 127 5861- -5880 coding 15931 AACCCATCGGCTGGCACCAC 128 5891- -5910 coding 15932 GTTTGAGCTCAGCCCCCTCA 129 6061- -6080 coding 15933 CTCCTCCCAGGTATATGGGC 130 6091- -6110 coding 15934 TGAGTTGGTCCCCCTTCTCC 131 6121- -6140 coding 15935 CAAAGTAGACCTGCCCGGAC 132 6181- -6200 coding 15936 ACACCCATTCCCTTCACAGA 133 6211- -6230 STOP 15937 CATAATCCCCTTTCTAAGTT 134 6321- -6340 3 ' -UTR 15938 CACAGAGTTGGACTCTGAGC 135 6341- -6360 3 ' -UTR 15939 CAGCATCTTGTGTTTCTGAG 136 6381- -6400 3 ' -UTR 15940 CACAGTCCAGGTCACTGTCC 137 6401- -6420 3 ' -UTR 15941 TGATGGTGGTGCATGAGAGG 138 6423- -6442 3 '-UTR 15942 GTGAATTCGGAAAGCCCATT 139 6451- -6470 3 * -UTR 15943 CCTGACCACTCTCCCTTTGC 140 6501- -6520 3* -UTR 3082 TGCATC ££CAGG£CA£CAT 141 target control 13108 GCCGAGGTCCATGTCGTACG 142 target control C All "C" residues are 5-methyl-cytosines except underlined "C" residues are unmodified cytosines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. Y00467, locus name "MMTNFAB", SEQ ID NO . 107. Results are shown in Table 19. Oligonucleotides 14853 (SEQ ID NO. 115), 14854 (SEQ ID NO. 116), 14855 (SEQ ID NO. 117), 15921 (SEQ ID NO. 118), 15923 (SEQ ID NO. 120), 15924 (SEQ ID NO. 121), 15925 (SEQ ID NO. 122), 15926 (SEQ ID NO. 123), 15929 (SEQ ID NO. 126), 15930 (SEQ ID NO. 127), 15931 (SEQ ID NO. 128), 15932 (SEQ ID NO. 129), 15934 (SEQ ID NO. 131), 15935 (SEQ ID NO. 132), 15936 (SEQ ID NO. 133), 15937 (SEQ ID NO. 134), 15939 (SEQ ID NO. 136), 15940 (SEQ ID NO. 137), 15942 (SEQ ID NO. 139), and 15943 (SEQ ID NO. 140) gave better than 50% inhibition. Oligonucleotides 15931 (SEQ ID NO. 128), 15932 (SEQ ID NO. 129), 15934 (SEQ ID NO. 131), and 15943 (SEQ ID NO. 140) gave 75% inhibition or better. TABLE 19 Inhibition of Mouse TNF-α mRNA expression in P388D1 Cells by Phosphorothioate Oligodeoxynucleotides ISIS SEQ GENE % mRNA % mRNA No: ID TARGET EXPRESSION INHIBITION NO: REGION induced 100% 0% 3082 141 control 129% 13664 42 control 85% 15% 14846 108 5 ' -UTR 84% 16% 14847 109 5' -UTR 88% 12% 14848 110 AUG 60% 40% 14849 111 AUG 75% 25% 14850 112 coding 67% 33% 14851 113 junction 62% 38% 14852 114 junction 69% 31% 14853 115 junction 49% 51% 14854 116 3' -UTR 31% 69% 14855 117 3 ' -UTR 39% 61% 15921 118 junction 42% 58% 15922 119 intron 64% 36% 15923 120 intron 31% 69% 15924 121 intron 29% 71% 15925 122 intron 30% 70% 15926 123 intron 29% 71% 15928 125 intron 59% 41% 15929 126 coding 38% 62% 15930 127 coding 43% 57% 15931 128 coding 23% 77% 15932 129 coding 25% 75% 15933 130 coding 52% 48% 15934 131 coding 21% 79% 15935 132 coding 39% 61% 15936 133 STOP 35% 65% 15937 134 3 ' -UTR 45% 55% 15938 135 3 ' -UTR 76% 24% 15939 136 3 ' -UTR 33% 67% 15940 137 3' -UTR 38% 62% 15941 138 3 '-UTR 54% 46% 15942 139 3' -UTR 42% 58% 15943 140 3 ' -UTR 25% 75% EXAMPLE 9: Dose response of antisense phosphorothiaote oligodeoxynucleotide effects on mouse TNF-α mRNA levels in P388D1 cells Four of the more active oligonucleotides from the initial screen were chosen for dose response assays. These include oligonucleotides 15924 (SEQ ID NO. 121) , 15931 (SEQ ID NO. 128), 15934 (SEQ ID NO. 131) and 15943 (SEQ ID NO. 140) . P388D1 cells were grown, treated and processed as described in Example 8. LIPOFECTIN ® was added at a ratio of 3 μg/ml per 100 nM of oligonucleotide. The control included LIPOFECTIN ® at a concentration of 6 μg/ml . Results are shown in Table 20. Each oligonucleotide tested showed a dose response effect with maximal inhibition about 70% or greater and IC 50 values less than 50 nM. TABLE 20 Dose Response of LPS-Induced P388D1 Cells to TNF-α Antisense Phosphorothioate Oligodeoxynucleotides (ASOs) SEQ ASO Gene % mRNA % mRNA ISIS # ID Target Dose Expression Inhibition NO: induced 100% 13108 142 ccoonnttrrooll 25 nM 68% 32% II 50 nM 71% 29% II 100 nM 64% 36% II 200 nM 75% 25% 15924 121 intron 25 nM 63% 37% II 50 nM 49% 51% II 100 nM 36% 64% II 200 nM 31% 69% 15931 128 coding 25 nM 42% 58% II 50 nM 30% 70% II 100 nM 17% 83% II 200 nM 16% 84% 15934 131 coding 25 nM 37% 63% II 50 nM 26% 74% II 100 nM 13% 87% II 200 nM 13% 87% 15943 140 3 '-UTR 25 nM 38% 62% II 50 nM 38% 62% " " " 100 nM 16% 84% " " " 200 nM 16% 84% EXAMPLE 10: Design and Testing of 2 ' -O-methoxyethyl (deoxy gapped) TNF-α Antisense Oligonucleotides on TNF-α Levels in P388D1 Cells Oligonucleotides having SEQ ID NO: 128, SEQ ID NO: 131, and SEQ ID NO: 140 were synthesized as uniformly phosphorothioate oligodeoxynucleotides or mixed phosphorothioate/phosphodiester chimeric oligonucleotides having variable regions of 2 ' -O-methoxyethyl (2' -MOE) nucleotides and deoxynucleotides . The sequences and the oligonucleotide chemistries are shown in Table 21. All 2'- MOE cytosines were 5-methyl-cytosines. Oligonucleotides were screened as described in Example 8. Results are shown in Table 22. All the oligonucleotides tested, except oligonucleotide 16817 (SEQ ID NO. 140) showed 44% or greater inhibition of TNF-α mRNA expression. Oligonucleotides 16805 (SEQ ID NO: 131) , 16813 (SEQ ID NO: 140), and 16814 (SEQ ID NO: 140) showed greater than 70% inhibition. TABLE 21 Nucleotide Sequences of Mouse 2 ■ -O-methoxyethyl (deoxy gapped) TNF-α Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 2 REGION 15931 AsAsCsCsCsAsTsCsGsGsCsTsGsGsCsAsCsCsAsC 128 5891 ■ 5910 coding 16797 AoAoCoCsCsAsTsCsGsGsCsTsGsGsCsAsCoCoAoC 5891 -5910 coding 16798 AsAsCsCsCsAsTsCsGsGsCsTsGsGsCsAsCsCsAsC 5891 -5910 coding 16799 AoAoCoCoCsAsTsCsGsGsCsTsGsGsCsAoCoCoAoC 5891 -5910 coding 16800 AsAsCsCsCsAsTsCsGsGsCsTsGsGsCsAsCsCsAsC 5891 -5910 coding CD 16801 AoAoCoCoCoAoToCoGsGsCsTsGsGsCsAsCsCsAsC 5891 -5910 coding 16802 AsAsCsCsCsAsTsCsGsGsCsTsGsGsCsAsCsCsAsC 5891 -5910 coding 16803 AsAsCsCsCsAsTsCsGsGsCsToGoGoCoAoCoCoAoC 5891 -5910 coding 16804 AsAsCsCsCsAsTsCsGsGsCsTsGsGsCsAsCsCsAsC 5891 -5910 coding 15934 TsGsAsGsTsTsGsGsTsCsCsCsCsCsTsTsCsTsCsC 131 6121 -6140 coding 16805 ToGoAoGsTsTsGsGsTsCsCsCsCsCsTsTsCoToCoC 6121 -6140 coding 16806 TsGsAsGsTsTsGsGsTsCsCsCsCsCsTsTsCsTsCsC 6121 -6140 coding 16807 ToGoAoGoTsTsGsGsTsCsCsCsCsCsTsToCoToCoC 6121 -6140 coding 16808 TsGsAsGsTsTsGsGsTsCsCsCsCsCsTsTsCsTsCsC 6121 -6140 coding TABLE 22 Inhibition of mouse TNF-α mRNA expression in P388D1 Cells by 2 * -O-methoxyethyl (deoxy gapped) Oligonucleotides ISIS SEQ GENE % mRNA % mRNA No: ID TARGET EXPRESSION INHIBITION NO: REGION induced 100% 0% 13108 142 control 87% 13% 15934 131 coding 28% 72% 16797 128 coding 33% 67% 16798 II coding 34% 66% 16799 II coding 56% 44% 16800 II coding 35% 65% 16801 II coding 34% 66% 16802 II coding 38% 62% 16803 II coding 35% 65% 16804 II coding 39% 61% 16805 131 coding 29% 71% 16806 II coding 31% 69% 16807 II coding 46% 54% 16808 II coding 43% 57% 16809 II coding 33% 67% 16810 II coding 37% 63% 16811 II coding 40% 60% 16812 II coding 31% 69% 16813 140 3' -UTR 28% 72% 16814 II 3' -UTR 28% 72% 16815 II 3 * -UTR 46% 54% 16816 II 3' -UTR 49% 51% 16817 II 3' -UTR 172% 16818 " 3 ' -UTR 34% 66% 16819 " 3 ' -UTR 51% 49% 16820 3' -UTR 44% 56% EXAMPLE 11: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Non-Insulin-dependent Diabetes Mellitus The db/db mouse model, a standard model for non- insulin-dependent diabetes mellitus (NIDDM; Hotamisligil,G.S. , et al . , Science, 1993, 259, 87-90), was used to assess the activity of TNF-α antisense oligonucleotides on blood glucose levels and TNF-α mRNA levels in whole mice. These mice have elevated blood glucose levels and TNF-α mRNA levels compared to wild type mice. Female db/db mice and wild-type littermates were purchased from Jackson Laboratories (Bar Harbor, ME) . The effect on oligonucleotide 15931 (SEQ ID NO. 128) on blood glucose levels was determined. For determination of TNF-α mRNA levels, oligonucleotide 15931 (SEQ ID NO. 128) , a uniformly modified phosphorothioate oligodeoxynucleotide, was compared to oligonucleotide 25302 (SEQ ID NO. 128), a mixed phosphorothioate/phosphodiester chimeric oligonucleotide having regions of 2 ' -O-methoxyethyl (2'- MOE) nucleotides and deoxynucleotides. The sequences and chemistries are shown in Table 23. Oligonucleotide 18154 (SEQ ID NO. 143) is an antisense mixed phosphorothioate/phosphodiester chimeric oligonucleotide, having regions of 2 ' -O-methoxyethyl (2' -MOE) nucleotides and deoxynucleotides, targeted to the human vascular cell adhesion molecule-1 (VCAM-1) and was used as an unrelated target control . TABLE 23 Nucleotide Sequence of TNF-α Antisense Oligonucleotide SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 2 REGION 15931 AACCCATCGGCTGGCACCAC 128 5891-5910 coding 25302 AACCCATCGGCTGGCACCAC 128 5891-5910 coding 18154 TCAAGCAGTGCCACCGATCC 143 target control 1 All 2 ' -methoxyethyl cytosines and 2 ' -deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. Y00467, locus name "MMTNFAB", SEQ ID NO. 107. db/db mice, six to ten weeks old, were dosed intraperitoneally with oligonucleotide every other day for 2 weeks at 10 mg/kg. The mice were fasted for seven hours prior to administration of the oligonucleotide. The mice were bled via retro orbital sinus every other day, and glucose measurements were performed on the blood. Results are shown in Table 24. Oligonucleotide 15931 (SEQ ID NO. 128) was able to reduce blood glucose levels in db/db mice to levels comparable with wild type mice. Food intake between wild type mice, treated and untreated, did not differ. Food intake between db/db mice, treated and untreated, although higher than wild type mice, did not differ significantly. Samples of the fat (adipose) tissue from the inguinal fat pads were taken for RNA extraction. RNA was extracted according to Current Protocols in Molecular Biology, 1997, Ausubel, F., et al . ed., John Wiley & Sons. RNA was purified using the RNA clean up procedure of the RNEASY ® Mini kit (Qiagen, Valencia, CA) . TNF-α mRNA levels were measured using the RIBOQUANT ® kit (PharMingen, San Diego, CA) with 15 μg of RNA per lane. The probe used was from the mCK-3b Multi-Probe Template set (PharMingen, San Diego, CA) labeled with [α 3 P] UTP (Amersham Pharmacia Biotech, Piscataway, NJ) . Results are shown in Table 25. Both oligonucleotide 15931 (SEQ ID NO. 128) and 25302 (SEQ ID NO. 128) were able to reduce TNF-α levels in fat, with 25302 (SEQ ID NO. 128) reducing TNF-α to nearly wild-type levels . TABLE 24 Level of Blood Glucose in Normal and db/db Mice After Treatment with TNF-α Antisense Oligonucleotides .SO Gene blood Mouse ISIS # NO: Target Time glucose Strain (days) (mg/dL) wild type 1 140 " 15931 128 coding II 138 db/db 1 260 " 15931 128 coding II 254 wild type --- 9 175 π 15931 128 coding II 163 db/db 9 252 " 15931 128 coding II 128 TABLE 25 Level of TNF-α mRNA in Fat of db/db Mice After Treatment with TNF-α Antisense Oligonucleotides ISIS SEQ GENE % mRNA No: ID TARGET EXPRESSION NO: REGION wt saline 100% db/db saline 362% 18154 142 control 130% 15931 128 coding 210% 25302 128 coding 417% EXAMPLE 12: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Rheumatoid Arthritis Collagen-induced arthritis (CIA) was used as a murine model for arthritis (Mussener,A. , et al . , Clin . Exp. Immunol . , 1997, 107, 485-493). Female DBA/lLacJ mice (Jackson Laboratories, Bar Harbor, ME) between the ages of 6 and 8 weeks were used to assess the activity of TNF-α antisense oligonucleotides. On day 0, the mice were immunized at the base of the tail with 100 μg of bovine type II collagen which is emulsified in Complete Freund's Adjuvant (CFA) . On day 7, a second booster dose of collagen was administered by the same route. On day 14, the mice were injected subcutaneously with 100 μg of LPS . Oligonucleotide was administered intraperitoneally daily (10 mg/kg bolus) starting on day -3 ( three days before day 0) and continuing for the duration of the study. Weights were recorded weekly. Mice were inspected daily for the onset of CIA. Paw widths are rear ankle widths of affected and unaffected joints were measured three times a week using a constant tension caliper. Limbs were clinically evaluated and graded on a scale from 0-4 (with 4 being the highest) . Oligonucleotide 25302 (SEQ ID NO. 128) was compared to a saline control. The antisense TNF-α oligonucleotide reduced the incidence of CIA from 70% for the saline control to 40% for the oligonucleotide. The severity of the disease (based on the mean score of the limbs) was also reduced from 3.2 for the saline control to 2.1 for the oligonucleotide . EXAMPLE 13: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Contact Sensitivity Contact sensitivity is a type of immune response resulting from contact of the surface of the skin with a sensitizing chemical . A murine model for contact sensitivity is widely used to develop therapies for chronic inflammation, autoimmune disorder, and organ transplant rejection (Goebeler,M. , et al . , Int Arch . Allergy Appl . Immunol . , 1990, 93 , 294-299). One example of such a disease is atopic dermatitis. Female Balb/c mice between the ages of 8 and 12 weeks are used to assess the activity of TNF-α antisense oligonucleotides in a contact sensitivity model . Balb/c mice receive injections of oligonucleotide drug in saline via i.v. injection into the tail vein. The abdomen of the mice is shaved using an Oster hair clipper. The animals are anesthesized using isoflurane, and 25 μl of 0.2% 2,4-dinitrofluorobenzene (DNFB) in 4:1 acetone: olive oil is applied to the shaved abdomen two days in a row. After five days, 10 ml of 0.2% DNFB in the same vehicle is applied to the right ear. After each exposure, the mouse is suspended in air for two minutes to allow the DNFB to absorb into the skin. 24 and 48 hours after application of DNFB to the ear, the ear thickness is measured using a micrometer. Inflammation (dermatitis) is indicated by a ranked thickening of the ear. Thickness of the treated ear is compared to untreated (contralateral) ear thickness. EXAMPLE 14: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Crohn's Disease C3H/HeJ, SJL/JK and IL10-/- mice are used in a TNBS (2,4, 5, -trinitrobenzene sulfonic acid) induced colitis model for Crohn's disease (Neurath,M.F. , et al . , J. Exp. Med. , 1995, 182, 1281-1290). Mice between the ages of 6 weeks and 3 months are used to assess the activity of TNF-α antisense oligonucleotides. C3H/HeJ, SJL/JK and IL10-/- mice are fasted overnight prior to administration of TNBS . A thin, flexible polyethylene tube is slowly inserted into the colon of the mice so that the tip rests approximately 4 cm proximal to the anus. 0.5 mg of the TNBS in 50% ethanol is slowly injected from the catheter fitted onto a 1 ml syringe. Animals are held inverted in a vertical position for approximately 30 seconds. TNF-α antisense oligonucleotides are administered either at the first sign of symptoms or simultaneously with induction of disease. Animals, in most cases, are dosed every day. Administration is by i.v., i.p., s.q., minipumps or intracolonic injection. Experimental tissues are collected at the end of the treatment regimen for histochemical evaluation. EXAMPLE 15: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Multiple Sclerosis Experimental autoimmune encephalomyelitis (EAE) is a commonly accepted murine model for multiple sclerosis (Myers, K.J., et al . , J. Neuroimmunol . , 1992, 41 , 1-8). SJL/H, PL/J, (SJLxPL/J)Fl, (SJLxBalb/c) FI and Balb/c female mice between the ages of 6 and 12 weeks are used to test the activity of TNF-α antisense oligonucleotides. The mice are immunized in the two rear foot pads and base of the tail with an emulsion consisting of encephalitogenic protein or peptide (according to Myers, K.J., et al . , J. of Immunol . , 1993, 151 , 2252-2260) in Complete Freund's Adjuvant supplemented with heat killed Mycobacterium tuberculosis. Two days later, the mice receive an intravenous injection of 500 ng Bordatella pertussis toxin and additional adjuvant. Alternatively, the disease may also be induced by the adoptive transfer of T-cells. T-cells are obtained from the draining of the lymph nodes of mice immunized with encephalitogenic protein or peptide in CFA. The T cells are grown in tissue culture for several days and then injected intravenously into naive syngeneic recipients. Mice are monitored and scored daily on a 0-5 scale for signals of the disease, including loss of tail muscle tone, wobbly gait, and various degrees of paralysis. EXAMPLE 16: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Pancreatitis Swiss Webster, C57BL/56, C57BL/6 lpr and gld male mice are used in an experimental pancreatitis model (Niederau,C. , et al . , Gastroenterology, 1985, 88, 1192- 1204) . Mice between the ages of 4 and 10 weeks are used to assess the activity of TNF-α antisense oligonucleotides. Caerulin (5-200 μg/kg) is administered i.p. every hour for one to six hours. At varying time intervals, the mice are given i.p. injection of avertin and bled by cardiac puncture. The pancreas and spleen are evaluated for histopathology and increased levels of IL-lβ, IL-6, and TNF-α. The blood is analyzed for increased levels of serum amylase and lipase. TNF-α antisense oligonucleotides are administered by intraperitoneal injection at 4 hours pre- caerulin injections. EXAMPLE 17: Effect of TNF-α Antisense Oligonucleotides in a Murine Model for Hepatitis Concanavalin A-induced hepatitis is used as a murine model for hepatitis (Mizuhara,H. , et al . , J. Exp . Med. , 1994, 179, 1529-1537) . It has been shown that this type of liver injury is mediated by Fas (Seino,K., et al . , Gastroenterology 1997, 113, 1315-1322) . Certain types of viral hepatitis, including Hepatitis C, are also mediated by Fas (J " . Gastroenterology and Hepatology, 1997, 12, S223- S226) . Female Balb/c and C57BL/6 mice between the ages of 6 weeks and 3 months are used to assess the activity of TNF-α antisense oligonucleotides. Mice are intravenenously injected with oligonucleotide. The pretreated mice are then intravenously injected with 0.3 mg concanavalin A (Con A) to induce liver injury. Within 24 hours following Con A injection, the livers are removed from the animals and analyzed for cell death (apoptosis) by in vi tro methods. In some experiments, blood is collected from the retro- orbital vein. EXAMPLE 18 : Effect of Antisense Oligonucleotide Targeted to TNF-α on Survival in Murine Heterotopic Heart Transplant Model To determine the therapeutic effects of TNF-α antisense oligonucleotides in preventing allograft rejection, murine TNF-α-specific oligonucleotides are tested for activity in a murine vascularized heterotopic heart transplant model. Hearts from Balb/c mice are transplanted into the abdominal cavity of C3H mice as primary vascularized grafts essentially as described by Isobe et al., Circulation 1991, 84, 1246-1255. Oligonucleotide is administered by continuous intravenous administration via a 7-day Alzet pump. The mean survival time for untreated mice is usually approximately 9-10 days. Treatment of the mice for 7 days with TNF-α antisense oligonucleotides is expected to increase the mean survival time. EXAMPLE 19: Optimization of Human TNF-α Antisense Oligonucleotide Additional antisense oligonucleotides targeted to intron 1 of human TNF-α were designed. These are shown in Table 26. Oligonucleotides are screened by RT-PCR as described in Example 5 hereinabove. TABLE 26 Nucleotide Sequences of Human TNF-α Intron 1 Antisense Oligonucleotides ISIS NUCLEOTIDE SEQUENCE 1 SEQ TARGET GENE GENE NO. (5' -> 3') ID NUCLEOTIDE TARGET NO: CO-ORDINATES 2 REGION 100181 AGTGTCTTCTGTGTGCCAGA 144 1409-1428 intron 1 100201 AGTGTCTTCTGTGTGCCAGA II intron 1 100230 AGTGTCTTCTGTGTGCCAGA II intron 1 100250 AGTGTCTTCTGTGTGCCAGA II intron 1 100182 GTGTCTTCTGTGTGCCAGAC 145 1408-1427 intron 1 100202 GTGTCTTCTGTGTGCCAGAC II intron 1 100231 GTGTCTTCTGTGTGCCAGAC II intron 1 100251 GTGTCTTCTGTGTGCCAGAC II intron 1 100183 TGTCTTCTGTGTGCCAGACA 146 1407-1426 intron 1 100203 TGTCTTCTGTGTGCCAGACA II intron 1 100232 TGTCTTCTGTGTGCCAGACA II intron 1 100252 TGTCTTCTGTGTGCCAGACA II intron 1 100184 GTCTTCTGTGTGCCAGACAC 147 1406-1425 intron 1 100204 GTCTTCTGTGTGCCAGACAC II intron 1 100233 GTCTTCTGTGTGCCAGACAC II intron 1 100253 GTCTTCTGTGTGCCAGACAC It intron 1 100185 TCTTCTGTGTGCCAGACACC 148 1405-1424 intron 1 100205 TCTTCTGTGTGCCAGACACC II intron 1 100234 TCTTCTGTGTGCCAGACACC II intron 1 100254 TCTTCTGTGTGCCAGACACC " " intron 1 100186 CTTCTGTGTGCCAGACACCC 149 1404-1423 intron 1 100206 CTTCTGTGTGCCAGACACCC " " intron 1 100235 CTTCTGTGTGCCAGACACCC " " intron 1 100255 CTTCTGTGTGCCAGACACCC " " intron 1 100187 TTCTGTGTGCCAGACACCCT 150 1403-1422 intron 1 100207 TTCTGTGTGCCAGACACCCT " " intron 1 100236 TTCTGTGTGCCAGACACCCT " " intron 1 100256 TTCTGTGTGCCAGACACCCT " " intron 1 100188 TCTGTGTGCCAGACACCCTA 151 1402-1421 intron 1 100208 TCTGTGTGCCAGACACCCTA " " intron 1 100237 TCTGTGTGCCAGACACCCTA " " intron 1 100257 TCTGTGTGCCAGACACCCTA " " intron 1 100189 CTGTGTGCCAGACACCCTAT 152 1401-1420 intron 1 100209 CTGTGTGCCAGACACCCTAT " " intron 1 100238 CTGTGTGCCAGACACCCTAT " " intron 1 100258 CTGTGTGCCAGACACCCTAT " " intron 1 100190 TGTGTGCCAGACACCCTATC 153 1400-1419 intron 1 100210 TGTGTGCCAGACACCCTATC " " intron 1 100239 TGTGTGCCAGACACCCTATC " " intron 1 100259 TGTGTGCCAGACACCCTATC " " intron 1 100191 TGTGCCAGACACCCTATCTT 154 1398-1417 intron 1 100211 TGTGCCAGACACCCTATCTT " " intron 1 100240 TGTGCCAGACACCCTATCTT " " intron 1 100260 TGTGCCAGACACCCTATCTT " " intron 1 100192 GTGCCAGACACCCTATCTTC 155 1397-1416 intron 1. 100212 GTGCCAGACACCCTATCTTC " " intron 1 100241 GTGCCAGACACCCTATCTTC " " intron 1 100261 GTGCCAGACACCCTATCTTC " " intron 1 100193 TGCCAGACACCCTATCTTCT 156 1396-1415 intron 1 100213 TGCCAGACACCCTATCTTCT " " intron 1 100242 TGCCAGACACCCTATCTTCT " " intron 1 100262 TGCCAGACACCCTATCTTCT " " intron 1 100194 GCCAGACACCCTATCTTCTT 157 1395-1414 intron 1 100214 GCCAGACACCCTATCTTCTT " " intron 1 100243 GCCAGACACCCTATCTTCTT " " intron 1 100263 GCCAGACACCCTATCTTCTT " " intron 1 100195 CCAGACACCCTATCTTCTTC 158 1394-1413 intron 1 100215 CCAGACACCCTATCTTCTTC " " intron 1 100244 CCAGACACCCTATCTTCTTC " " intron 1 100264 CCAGACACCCTATCTTCTTC " " intron 1 100196 CAGACACCCTATCTTCTTCT 159 1393-1412 intron 1 100216 CAGACACCCTATCTTCTTCT " " intron 1 100245 CAGACACCCTATCTTCTTCT " " intron 1 100265 CAGACACCCTATCTTCTTCT " " intron 1 100197 AGACACCCTATCTTCTTCTC 160 1392-1411 intron 1 100217 AGACACCCTATCTTCTTCTC " " intron 1 100246 AGACACCCTATCTTCTTCTC " " intron 1 100266 AGACACCCTATCTTCTTCTC " " intron 1 100198 GACACCCTATCTTCTTCTCT 161 1391-1410 intron 1 100218 GACACCCTATCTTCTTCTCT " " intron 1 100247 GACACCCTATCTTCTTCTCT " " intron 1 100267 GACACCCTATCTTCTTCTCT " " intron 1 100199 ACACCCTATCTTCTTCTCTC 162 1390-1409 intron 1 100219 ACACCCTATCTTCTTCTCTC " " intron 1 100248 ACACCCTATCTTCTTCTCTC " " intron 1 100268 ACACCCTATCTTCTTCTCTC " " intron 1 100200 CACCCTATCTTCTTCTCTCC 163 1389-1408 intron 1 100220 CACCCTATCTTCTTCTCTCC II 1II intron 1 100249 CACCCTATCTTCTTCTCTCC II 1 II intron 1 100269 CACCCTATCTTCTTCTCTCC II 1 II intron 1 100270 GTCTTCTGTGTGCCAGAC 164 1408- -1425 intron 1 100271 TCTTCTGTGTGCCAGACA 165 1407- -1424 intron 1 100272 CTTCTGTGTGCCAGACAC 166 1406- -1423 intron 1 100273 TTCTGTGTGCCAGACACC 167 1405- -1422 intron 1 100274 TCTGTGTGCCAGACACCC 168 1404- -1421 intron 1 100275 CTGTGTGCCAGACACCCT 169 1403- -1420 intron 1 100276 TGTGTGCCAGACACCCTA 170 1402- -1419 intron 1 100277 GTGTGCCAGACACCCTAT 171 1401- -1418 intron 1 100278 TGTGCCAGACACCCTATC 172 1400- -1417 intron 1 100279 TGCCAGACACCCTATCTT 173 1398- -1415 intron 1 100280 GCCAGACACCCTATCTTC 174 1397- -1414 intron 1 100281 CCAGACACCCTATCTTCT 175 1396- -1413 intron 1 100282 CAGACACCCTATCTTCTT 176 1395- -1412 intron 1 100283 AGACACCCTATCTTCTTC 177 1394- -1411 intron 1 100284 GACACCCTATCTTCTTCT 178 1393- -1410 intron 1 100285 ACACCCTATCTTCTTCTC 179 1392- -1409 intron 1 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2 ' -methoxyethyl cytosines and 2 ' -deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. EXAMPLE 20: Design of Antisense Oligonucleotides Targeting Human TNF-α Intron 2 Additional antisense oligonucleotides targeted to intron 2 and coding regions of human TNF-α were designed. These are shown in Table 27. Oligonucleotides are screened by RT-PCR as described in Example 5 hereinabove. TABLE 27 Nucleotide Sequences of Human TNF-α Intron 2 Antisense Oligonucleotides ISIS NUCLEOTIDE SEQUENCE 1 SEQ TARGET GENE GENE No. (5' -> 3') ID NUCLEOTIDE TARGET NO: CO-ORDINATES 2 REGION 100549 AGAGGTTTGGAGACACTTAC 180 1635-1654 intron 2 100566 AGAGGTTTGGAGACACTTAC intron 2 100550 GAATTAGGAAAGAGGTTTGG 181 1645-1664 intron 2 100567 GAATTAGGAAAGAGGTTTGG intron 2 100551 CCCAAACCCAGAATTAGGAA 182 1655-1674 intron 2 100568 CCCAAACCCAGAATTAGGAA intron 2 100552 TACCCCCAAACCCAAACCCA 183 1665-1684 intron 2 100569 TACCCCCAAACCCAAACCCA intron 2 100553 GTACTAACCCTACCCCCAAA 184 1675-1694 intron 2 100570 GTACTAACCCTACCCCCAAA intron 2 100554 TTCCATACCGGTACTAACCC 185 1685-1704 intron 2 100571 TTCCATACCGGTACTAACCC intron 2 100555 CCCCCACTGCTTCCATACCG 186 1695-1714 intron 2 100572 CCCCCACTGCTTCCATACCG intron 2 100556 CTTTAAATTTCCCCCACTGC 187 1705-1724 intron 2 100573 CTTTAAATTTCCCCCACTGC intron 2 100557 AAGACCAAAACTTTAAATTT 188 1715-1734 intron 2 100571 AAGACCAAAACTTTAAATTT intron 2 100558 ATCCTCCCCCAAGACCAAAA 189 1725-1744 intron 2 100640 ATCCTCCCCCAAGACCAAAA II II intron 2 100559 ACCTCCATCCATCCTCCCCC 190 1735 -1754 intron 2 100641 ACCTCCATCCATCCTCCCCC II II intron 2 100560 CCCTACTTTCACCTCCATCC 191 1745 -1764 intron 2 100642 CCCTACTTTCACCTCCATCC II II intron 2 100561 GAAAATACCCCCCTACTTTC 192 1755 -1774 intron 2 100643 GAAAATACCCCCCTACTTTC II II intron 2 100562 AAACTTCCTAGAAAATACCC 193 1765 -1784 intron 2 100644 AAACTTCCTAGAAAATACCC II II intron 2 100563 TGAGACCCTTAAACTTCCTA 194 1775- -1794 intron 2 100645 TGAGACCCTTAAACTTCCTA II 1 II intron 2 100564 AAGAAAAAGCTGAGACCCTT 195 1785- -1804 intron 2 100646 AAGAAAAAGCTGAGACCCTT II 1 II intron 2 100565 GGAGAGAGAAAAGAAAAAGC 196 1795- -1814 intron 2 100647 GGAGAGAGAAAAGAAAAAGC II 1 ! l intron 2 100575 TGAGCCAGAAGAGGTTGAGG 197 2665- -2684 coding 100576 ATTCTCTTTTTGAGCCAGAA 198 2675- -2694 coding 100577 TAAGCCCCCAATTCTCTTTT 199 2685- -2704 coding 100578 GTTCCGACCCTAAGCCCCCA 200 2695- -2714 coding 100579 CTAAGCTTGGGTTCCGACCC 201 2705- -2724 coding 100580 GCTTAAAGTTCTAAGCTTGG 202 2715- -2734 coding 100581 TGGTCTTGTTGCTTAAAGTT 203 2725- -2744 coding 100582 TTCGAAGTGGTGGTCTTGTT 204 2735- -2754 coding 100583 AATCCCAGGTTTCGAAGTGG 205 2745- -2764 coding 100584 CACATTCCTGAATCCCAGGT 206 2755- -2774 coding 100585 GTGCAGGCCACACATTCCTG 207 2765- -2784 coding 100586 GCACTTCACTGTGCAGGCCA 208 2775- -2794 coding 100587 GTGGTTGCCAGCACTTCACT 209 2785- -2804 coding 100588 TGAATTCTTAGTGGTTGCCA 210 2795- -2814 coding 100589 GGCCCCAGTTTGAATTCTTA 211 2805- -2824 coding 100590 GAGTTCTGGAGGCCCCAGTT 212 2815 -2834 coding 100591 AGGCCCCAGTGAGTTCTGGA 32 2825 -2844 coding 100592 TCAAAGCTGTAGGCCCCAGT 214 2835- -2854 coding 100593 ATGTCAGGGATCAAAGCTGT 215 2845- -2864 coding 100594 CAGATTCCAGATGTCAGGGA 216 2855- -2874 coding 100595 CCCTGGTCTCCAGATTCCAG 217 2865- -2884 coding 100596 ACCAAAGGCTCCCTGGTCTC 218 2875- -2894 coding 100597 TCTGGCCAGAACCAAAGGCT 219 2885- -2904 coding 100598 CCTGCAGCATTCTGGCCAGA 220 2895- -2914 coding 100599 CTTCTCAAGTCCTGCAGCAT 221 2905- -2924 coding 100600 TAGGTGAGGTCTTCTCAAGT 222 2915- -2934 coding 100601 TGTCAATTTCTAGGTGAGGT 223 2925- -2944 coding 100602 GGTCCACTTGTGTCAATTTC 224 2935- -2954 coding 100603 GAAGGCCTAAGGTCCACTTG 225 2945- -2964 coding 100604 CTGGAGAGAGGAAGGCCTAA 226 2955- -2974 coding 100605 CTGGAAACATCTGGAGAGAG 227 2965- -2984 coding 100606 TCAAGGAAGTCTGGAAACAT 228 2975- -2994 coding 100607 GCTCCGTGTCTCAAGGAAGT 229 2985- -3004 coding 100608 ATAAATACATTCATCTGTAA 230 3085- -3104 coding 100609 GGTCTCCCAAATAAATACAT 231 3095- -3114 coding 100610 AGGATACCCCGGTCTCCCAA 232 3105- -3124 coding 100611 TGGGTCCCCCAGGATACCCC 35 3115- -3134 coding 100612 GCTCCTACATTGGGTCCCCC 234 3125- -3144 coding 100613 AGCCAAGGCAGCTCCTACAT 235 3135- -3154 coding 100614 AACATGTCTGAGCCAAGGCA 236 3145- -3164 coding 100615 TTTCACGGAAAACATGTCTG 237 3155- -3174 coding 100616 TCAGCTCCGTTTTCACGGAA 238 3165- -3184 coding 100617 AGCCTATTGTTCAGCTCCGT 239 3175- -3194 coding 100618 ACATGGGAACAGCCTATTGT 240 3185- -3204 coding 100619 ATCAAAAGAAGGCACAGAGG 241 3215--3234 coding 100620 GTTTAGACAACTTAATCAGA 242 3255- -3274 coding 100621 AATCAGCATTGTTTAGACAA 243 3265- -3284 coding 100622 TTGGTCACCAAATCAGCATT 244 3275- -3294 coding 100623 TGAGTGACAGTTGGTCACCA 245 3285- -3304 coding 100624 GGCTCAGCAATGAGTGACAG 246 3295- -3314 coding 100625 ATTACAGACACAACTCCCCT 247 3325- -3344 coding 100626 TAGTAGGGCGATTACAGACA 248 3335- -3354 coding 100627 CGCCACTGAATAGTAGGGCG 249 3345- -3364 coding 100628 CTTTATTTCTCGCCACTGAA 250 3355- -3374 coding 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2 ' -methoxyethyl cytosines and 2 ' -deoxy cytosines residues are 5-methyl-cytosines ; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. Several of these oligonucleotides were chosen for dose response studies. Cells were grown and treated as described in Example 3. Results are shown in Table 28. Each oligonucleotide tested showed a dose response curve with maximum inhibition greater than 75%. TABLE 28 Dose Response of PMA-Induced neoHK Cells to TNF-α Antisense Oligonucleotides (ASOs) SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 100% 100235 149 intron 1 75 nM 77% 23% II II II 150 nM 25% 75% II II II 300 nM 6% 94% 100243 157 intron 1 75 nM 68% 32% II II II 150 nM 15% 85% II II II 300 nM 6% 94% 100263 157 intron 1 75 nM 79% 21% II II II 150 nM 30% 70% II II II 300 nM 23% 77% EXAMPLE 21: Optimization of Human TNF-α Antisense Oligonucleotide Chemistry Analogs of oligonucleotides 21820 (SEQ ID NO. 66 ) and 21823 (SEQ ID NO. 69) were designed and synthesized to find an optimum gap size. The sequences and chemistries are shown in Table 29. Dose response experiments were performed as described in Example 3. Results are shown in Table 30. TABLE 29 Nucleotide Sequences of TNF-α Chimeric Backbone (deoxy gapped) Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: COREGION ORDINATES 1 21820 ATATTTCCCGCTCTTTCTGT 66 1339-1358 intron 1 28086 ATATTTCCCGCTCTTTCTGT " " " 28087 ATATTTCCCGCTCTTTCTGT " " " 21823 GTGTGCCAGACACCCTATCT 69 1399-1418 intron 1 28088 GTGTGCCAGACACCCTATCT " " " 28089 GTGTGCCAGACACCCTATCT " " " 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2 ' -methoxyethoxy cytidines and 2'- deoxycytidines are 5-methyl-cytidines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. TABLE 30 Dose Response of 20 Hour PMA-Induced neoHK Cells to TNF-α Chimeric (deoxy gapped) Antisense Oligonucleotides (ASOs) SEQ ASO Gene % protein % protein ISIS # ID Target Dose Expression Inhibition NO: induced 100% 13393 49 control 75 nM 150.0% II II II 150 nM 135.0% II II II 300 nM 90.0% 10.0% 21820 66 intron 1 75 nM 65.0% 35.0% II II II 150 nM 28.0% 72.0% II II II 300 nM 9.7% 90.3% 28086 66 intron 1 75 nM 110.0% II II II 150 nM 83.0% 17.0% II II II 300 nM 61.0% 39.0% 28087 66 intron 1 75 nM 127.0% II II II 150 nM 143.0% II II II 300 nM 147.0% 21823 69 intron 1 75 nM 35.0% 65.0% II II II 150 nM 30.0% 70.0% II II II 300 nM 6.4% 93.6% 28088 69 intron 1 75 nM 56.0% 44.0% II II II 150 nM 26.0% 74.0% II II II 300 nM 11.0% 89.0% 28089 69 intron 1 75 nM 76.0% 24.0% II II II 150 nM 53.0% 47.0% II II II 300 nM 23.0% 77.0% EXAMPLE 22: Screening of additional TNF-α chimeric (deoxy gapped) antisense oligonucleotides Additional oligonucleotides targeting the major regions of TNF-α were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having regions of five 2 ' -O-methoxyethyl (2' -MOE) nucleotides at the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 31. Oligonucleotides were screened as described in Example 5. Results are shown in Table 32. TABLE 31 Nucleotide Sequence of Additional Human TNF-α Chimeric (deoxy gapped) Antisense Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO-ORDINATES 2 REGION 104649 CTGAGGGAGCGTCTGCTGGC 251 0616- -0635 5' -UTR 104650 CCTTGCTGAGGGAGCGTCTG 252 0621- -0640 5' -UTR 104651 CTGGTCCTCTGCTGTCCTTG 253 0636- -0655 5' -UTR 104652 CCTCTGCTGTCCTTGCTGAG 254 0631- -0650 5' -UTR 104653 TTCTCTCCCTCTTAGCTGGT 255 0651- -0670 5' -UTR 104654 TCCCTCTTAGCTGGTCCTCT 256 0646- -0665 5' -UTR 104655 TCTGAGGGTTGTTTTCAGGG 257 0686- -0705 5' -UTR 104656 CTGTAGTTGCTTCTCTCCCT 258 0661- -0680 5' -UTR 104657 ACCTGCCTGGCAGCTTGTCA 259 0718- -0737 5* -UTR 104658 GGATGTGGCGTCTGAGGGTT 260 0696- -0715 5' -UTR 104659 TGTGAGAGGAAGAGAACCTG 261 0733- -0752 5' -UTR 104660 GAGGAAGAGAACCTGCCTGG 262 0728- -0747 5* -UTR 104661 AGCCGTGGGTCAGTATGTGA 263 0748- -0767 5' -UTR 104662 TGGGTCAGTATGTGAGAGGA 264 0743- -0762 5' -UTR 104663 GAGAGGGTGAAGCCGTGGGT 265 0758--0777 5' -UTR 104664 TCATGGTGTCCTTTCCAGGG 266 0780- -0799 AUG 104665 CTTTCAGTGCTCATGGTGTC 267 0790- -0809 AUG 104666 TCATGCTTTCAGTGCTCATG 268 0795- -0814 AUG 104667 ACGTCCCGGATCATGCTTTC 269 0805- -0824 coding 104668 GCTCCACGTCCCGGATCATG 270 0810- -0829 coding 104669 TCCTCGGCCAGCTCCACGTC 271 0820- -0839 coding 104670 GCGCCTCCTCGGCCAGCTCC 272 0825- -0844 coding 104671 AGGAACAAGCACCGCCTGGA 273 0874- -0893 coding 104672 CAAGCACCGCCTGGAGCCCT 274 0869- -0888 coding 104673 AAGGAGAAGAGGCTGAGGAA 275 0889- -0908 coding 104674 GAAGAGGCTGAGGAACAAGC 276 0884- -0903 coding 104675 CCTGCCACGATCAGGAAGGA 277 0904- -0923 coding 104676 CACGATCAGGAAGGAGAAGA 278 0899- -0918 coding 104677 AAGAGCGTGGTGGCGCCTGC 279 0919- -0938 coding 104678 CGTGGTGGCGCCTGCCACGA 280 0914- -0933 coding 104679 AAGTGCAGCAGGCAGAAGAG 281 0934- -0953 coding 104680 CAGCAGGCAGAAGAGCGTGG 282 0929- -0948 coding 104681 GATCACTCCAAAGTGCAGCA 283 0944- -0963 coding 104682 GGGCCGATCACTCCAAAGTG 284 0949- -0968 coding 104683 GGGCCAGAGGGCTGATTAGA 285 1606- -1625 coding 104684 AGAGGGCTGATTAGAGAGAG 286 1601- -1620 coding 104685 GCTACAGGCTTGTCACTCGG 287 1839- -1858 coding 104686 CTGACTGCCTGGGCCAGAGG 288 1616- -1635 E2/I2 3 104687 TACAACATGGGCTACAGGCT 289 1849- -1868 coding 104688 AGCCACTGGAGCTGCCCCTC 290 2185- -2204 coding 104689 CTGGAGCTGCCCCTCAGCTT 291 2180- -2199 coding 104690 TTGGCCCGGCGGTTCAGCCA 292 2200- -2219 coding 104691 TTGGCCAGGAGGGCATTGGC 293 2215- ■ 2234 coding 104692 CCGGCGGTTCAGCCACTGGA 294 2195--2214 coding 104693 CTCAGCTCCACGCCATTGGC 295 2230- -2249 coding 104694 CAGGAGGGCATTGGCCCGGC 296 2210- -2229 coding 104695 CTCCACGCCATTGGCCAGGA 297 2225- -2244 coding 104696 ACCAGCTGGTTATCTCTCAG 298 2245- -2264 coding 104697 CTGGTTATCTCTCAGCTCCA 299 2240- -2259 coding 104698 CCCTCTGATGGCACCACCAG 300 2260- -2279 coding 104699 TGATGGCACCACCAGCTGGT 301 2255- -2274 coding 104700 TAGATGAGGTACAGGCCCTC 302 2275- -2294 coding 104701 AAGAGGACCTGGGAGTAGAT 303 2290- -2309 coding 104702 GAGGTACAGGCCCTCTGATG 304 2270- -2289 coding 104703 CAGCCTTGGCCCTTGAAGAG 305 2305- -2324 coding 104704 GACCTGGGAGTAGATGAGGT 306 2285- -2304 coding 104705 TTGGCCCTTGAAGAGGACCT 307 2300- -2319 coding 104706 TGGTGTGGGTGAGGAGCACA 308 2337- -2356 coding 104707 CGGCGATGCGGCTGATGGTG 309 2352- -2371 coding 104708 TGGGTGAGGAGCACATGGGT 310 2332- -2351 coding 104709 TGGTCTGGTAGGAGACGGCG 311 2367- -2386 coding 104710 ATGCGGCTGATGGTGTGGGT 312 2347- -2366 coding 104711 AGAGGAGGTTGACCTTGGTC 313 2382- -2401 coding 104712 TGGTAGGAGACGGCGATGCG 314 2362- -2381 coding 104713 AGGTTGACCTTGGTCTGGTA 315 2377- -2396 coding 104714 GGCTCTTGATGGCAGAGAGG 316 2397- -2416 coding 104715 TCATACCAGGGCTTGGCCTC 317 2446- -2465 coding 104716 TTGATGGCAGAGAGGAGGTT 318 2392- -2411 coding 104717 CCCAGATAGATGGGCTCATA 93 2461- -2480 coding 104718 CCAGGGCTTGGCCTCAGCCC 94 2441- -2460 coding 104719 AGCTGGAAGACCCCTCCCAG 319 2476- -2495 coding 104720 ATAGATGGGCTCATACCAGG 320 2456- -2475 coding 104721 CGGTCACCCTTCTCCAGCTG 321 2491 -2510 coding 104722 GAAGACCCCTCCCAGATAGA 322 2471 -2490 coding 104723 ATCTCAGCGCTGAGTCGGTC 26 2506 -2525 coding 104724 ACCCTTCTCCAGCTGGAAGA 323 2486 -2505 coding 104725 TAGTCGGGCCGATTGATCTC 90 2521 -2540 coding 104726 AGCGCTGAGTCGGTCACCCT 91 2501 -2520 coding 104727 TCGGCAAAGTCGAGATAGTC 324 2536 -2554 coding 104728 GGGCCGATTGATCTCAGCGC 325 2516- -2535 coding 104729 TAGACCTGCCCAGACTCGGC 326 2551- -2570 coding 104730 AAAGTCGAGATAGTCGGGCC 327 2531- -2550 coding 104731 GCAATGATCCCAAAGTAGAC 328 2566- -2585 coding 104732 CTGCCCAGACTCGGCAAAGT 329 2546- -2565 coding 104733 CGTCCTCCTCACAGGGCAAT 330 2581- -2600 stop 104734 GATCCCAAAGTAGACCTGCC 88 2561- -2580 coding 104735 GGAAGGTTGGATGTTCGTCC 331 2596- -2615 3 ' -UTR 104736 TCCTCACAGGGCAATGATCC 332 2576- -2595 stop 104737 GTTGAGGGTGTCTGAAGGAG 333 2652- -2671 3 ' -UTR 104738 GTTGGATGTTCGTCCTCCTC 334 2591- -2610 stop 104739 TTTGAGCCAGAAGAGGTTGA 335 2667- -2686 3 ' -UTR 104740 GAGGCGTTTGGGAAGGTTGG 336 2606- -2625 3 ' -UTR 104741 GCCCCCAATTCTCTTTTTGA 337 2682- -2701 3 ' -UTR 104742 GCCAGAAGAGGTTGAGGGTG 338 2662- -2681 3' -UTR 104743 GGGTTCCGACCCTAAGCCCC 339 2697- -2716 3 ' -UTR 104744 CAATTCTCTTTTTGAGCCAG 340 2677- -2696 3 ' -UTR 104745 TAAAGTTCTAAGCTTGGGTT 341 2712- -2731 3 ' -UTR 104746 CCGACCCTAAGCCCCCAATT 342 2692- -2711 3 ' -UTR 104747 GGTGGTCTTGTTGCTTAAAG 343 2727- -2746 3 ' -UTR 104748 TTCTAAGCTTGGGTTCCGAC 344 2707- -2726 3' -UTR 104749 CCCAGGTTTCGAAGTGGTGG 345 2742- -2761 3 ' -UTR 104750 TCTTGTTGCTTAAAGTTCTA 346 2722 -2741 3 ■ -UTR 104751 CACACATTCCTGAATCCCAG 347 2757 -2776 3 -UTR 104752 GTTTCGAAGTGGTGGTCTTG 348 2737 -2756 3 -UTR 104753 CTTCACTGTGCAGGCCACAC 349 2772 -2791 3 -UTR 104754 ATTCCTGAATCCCAGGTTTC 350 2752 -2771 3 -UTR 104755 TAGTGGTTGCCAGCACTTCA 351 2787 -2806 3 -UTR 104756 CCCAGTTTGAATTCTTAGTG 352 2802- -2821 3 -UTR 104757 CTGTGCAGGCCACACATTCC 353 2767 -2786 3 -UTR 104758 GTGAGTTCTGGAGGCCCCAG 354 2817 -2836 3 -UTR 104759 GTTGCCAGCACTTCACTGTG 355 2782- -2801 3 -UTR 104760 TTTGAATTCTTAGTGGTTGC 356 2797 -2816 3 -UTR 104761 AAGCTGTAGGCCCCAGTGAG 357 2832- -2851 3 -UTR 104762 TTCTGGAGGCCCCAGTTTGA 358 2812- -2831 3 -UTR 104763 AGATGTCAGGGATCAAAGCT 359 2847- -2866 3 -UTR 104764 TGGTCTCCAGATTCCAGATG 360 2862- -2881 3 -UTR 104765 GTAGGCCCCAGTGAGTTCTG 361 2827- -2846 3 -UTR 104766 GAACCAAAGGCTCCCTGGTC 362 2877- -2896 3 -UTR 104767 TCAGGGATCAAAGCTGTAGG 363 2842- -2861 3 -UTR 104768 TCCAGATTCCAGATGTCAGG 364 2857- -2876 3 -UTR 104769 GCAGCATTCTGGCCAGAACC 365 2892- -2911 3 -UTR 104770 GTCTTCTCAAGTCCTGCAGC 366 2907- -2926 3 -UTR 104771 AAAGGCTCCCTGGTCTCCAG 367 2872- -2891 3 -UTR 104772 CAATTTCTAGGTGAGGTCTT 368 2922- -2941 3 -UTR 104773 ATTCTGGCCAGAACCAAAGG 369 2887- -2906 3 -UTR 104774 CTCAAGTCCTGCAGCATTCT 34 2902- -2921 3 -UTR 104775 AAGGTCCACTTGTGTCAATT 370 2937- -2956 3 -UTR 104776 GAGAGAGGAAGGCCTAAGGT 371 2952- -2971 3 -UTR 104777 TCTAGGTGAGGTCTTCTCAA 372 2917- -2936 3 -UTR 104778 CCACTTGTGTCAATTTCTAG 373 2932- -2951 3 -UTR 104779 GTCTGGAAACATCTGGAGAG 374 2967 -2986 3 ' -UTR 104780 CCGTGTCTCAAGGAAGTCTG 375 2982 -3001 3 '-UTR 104781 AGGAAGGCCTAAGGTCCACT 376 2947 -2966 3 -UTR 104782 GAGGGAGCTGGCTCCATGGG 377 3014 -3033 3 -UTR 104783 GAAACATCTGGAGAGAGGAA 378 2962 -2981 3 -UTR 104784 GTGCAAACATAAATAGAGGG 379 3029 -3048 3 -UTR 104785 TCTCAAGGAAGTCTGGAAAC 380 2977 -2996 3 -UTR 104786 AATAAATAATCACAAGTGCA 381 3044- -3063 3 -UTR 104787 GGGCTGGGCTCCGTGTCTCA 382 2992- -3011 3 -UTR 104788 TACCCCGGTCTCCCAAATAA 383 3101- -3120 3 -UTR 104789 AACATAAATAGAGGGAGCTG 384 3024- -3043 3 -UTR 104790 TTGGGTCCCCCAGGATACCC 385 3116- -3135 3 -UTR 104791 ATAATCACAAGTGCAAACAT 386 3039- -3058 3 -UTR 104792 AAGGCAGCTCCTACATTGGG 387 3131- -3150 3 -UTR 104793 CGGTCTCCCAAATAAATACA 388 3096- -3115 3 -UTR 104794 AAACATGTCTGAGCCAAGGC 389 3146- -3165 3 -UTR 104795 TCCCCCAGGATACCCCGGTC 390 3111- -3130 3 -UTR 104796 AGCTCCTACATTGGGTCCCC 391 3126- -3145 3 -UTR 104797 CTCCGTTTTCACGGAAAACA 37 3161- -3180 3 -UTR 104798 TGTCTGAGCCAAGGCAGCTC 392 3141- -3160 3 -UTR 104799 CAGCCTATTGTTCAGCTCCG 393 3176- -3195 3' -UTR 104800 AGAAGGCACAGAGGCCAGGG 394 3209- -3228 3' -UTR 104801 TTTTCACGGAAAACATGTCT 395 3156- -3175 3 -UTR 104802 TATTGTTCAGCTCCGTTTTC 396 3171- -3190 3 -UTR 104803 AAAAACATAATCAAAAGAAG 397 3224- -3243 3' -UTR 104804 CAGATAAATATTTTAAAAAA 398 3239- -3258 3" -UTR 104805 TACATGGGAACAGCCTATTG 399 3186- -3205 3 -UTR 104806 TTTAGACAACTTAATCAGAT 400 3254- -3273 3' -UTR 104807 CATAATCAAAAGAAGGCACA 401 3219- -3238 3' -UTR 104808 ACCAAATCAGCATTGTTTAG 402 3269 -3288 3 ■ -UTR 104809 AAATATTTTAAAAAACATAA 403 3234 -3253 3 • -UTR 104810 GAGTGACAGTTGGTCACCAA 404 3284 -3303 3 -UTR 104811 ACAACTTAATCAGATAAATA 405 3249 -3268 3 -UTR 104812 CAGAGGCTCAGCAATGAGTG 406 3299 -3318 3 -UTR 104813 ATCAGCATTGTTTAGACAAC 407 3264 -3283 3 -UTR 104814 AGGGCGATTACAGACACAAC 408 3331- -3350 3 -UTR 104815 ACAGTTGGTCACCAAATCAG 409 3279- -3298 3 -UTR 104816 TCGCCACTGAATAGTAGGGC 410 3346- -3365 3 -UTR 104817 GCTCAGCAATGAGTGACAGT 411 3294- -3313 3 -UTR 104818 AGCAAACTTTATTTCTCGCC 412 3361- -3380 3 -UTR 104819 GATTACAGACACAACTCCCC 413 3326- -3345 3 -UTR 104820 ACTGAATAGTAGGGCGATTA 414 3341- -3360 3 -UTR 104821 ACTTTATTTCTCGCCACTGA 415 3356- -3375 3 -UTR 104822 GCTGTCCTTGCTGAGGGAGC 416 0626- -0645 5 -UTR 104823 CTTAGCTGGTCCTCTGCTGT 417 0641- -0660 5 -UTR 104824 GTTGCTTCTCTCCCTCTTAG 418 0656- -0675 5 -UTR 104825 TGGCGTCTGAGGGTTGTTTT 419 0691- -0710 5' -UTR 104826 AGAGAACCTGCCTGGCAGCT 420 0723- -0742 5' -UTR 104827 CAGTATGTGAGAGGAAGAGA 421 0738- -0757 5' -UTR 104828 GGTGAAGCCGTGGGTCAGTA 422 0753- -0772 5' -UTR 104829 AGTGCTCATGGTGTCCTTTC 423 0785- -0804 AUG 104830 CCGGATCATGCTTTCAGTGC 424 0800- -0819 coding 104831 GGCCAGCTCCACGTCCCGGA 425 0815- -0834 coding 104832 GGCCCCCCTGTCTTCTTGGG 426 0847- • 0866 coding 104833 GGCTGAGGAACAAGCACCGC 427 0879- 0898 coding 104834 TCAGGAAGGAGAAGAGGCTG 428 0894- -0913 coding 104835 TGGCGCCTGCCACGATCAGG 429 0909- • 0918 coding 104836 GGCAGAAGAGCGTGGTGGCG 430 0924- 0943 cc )ding 104837 CTCCAAAGTGCAGCAGGCAG 431 0939--0958 coding 104838 GCTGATTAGAGAGAGGTCCC 432 1596- -1615 coding 104839 TGCCTGGGCCAGAGGGCTGA 433 1611- -1630 coding 104840 GCTGCCCCTCAGCTTGAGGG 434 2175- -2194 coding 104841 GGTTCAGCCACTGGAGCTGC 435 2190- -2209 coding 104842 GGGCATTGGCCCGGCGGTTC 436 2205- -2224 coding 104843 CGCCATTGGCCAGGAGGGCA 437 2220- -2239 coding 104844 TATCTCTCAGCTCCACGCCA 438 2235- -2254 coding 104845 GCACCACCAGCTGGTTATCT 439 2250- -2269 coding 104846 ACAGGCCCTCTGATGGCACC 440 2265- -2284 coding 104847 GGGAGTAGATGAGGTACAGG 441 2280- -2299 coding 104848 CCTTGAAGAGGACCTGGGAG 442 2295- -2314 coding 104849 GAGGAGCACATGGGTGGAGG 443 2327- -2346 coding 104850 GCTGATGGTGTGGGTGAGGA 444 2342- -2361 coding 104851 GGAGACGGCGATGCGGCTGA 445 2357- -2376 coding 104852 GACCTTGGTCTGGTAGGAGA 446 2372- -2391 coding 104853 GGCAGAGAGGAGGTTGACCT 447 2387- -2406 coding 104854 GCTTGGCCTCAGCCCCCTCT 23 2436- -2455 coding 104855 TGGGCTCATACCAGGGCTTG 448 2451- -2470 coding 104856 CCCCTCCCAGATAGATGGGC 449 2466- -2485 coding 104857 TCTCCAGCTGGAAGACCCCT 92 2481- -2500 coding 104858 TGAGTCGGTCACCCTTCTCC 450 2496- -2515 coding 104859 GATTGATCTCAGCGCTGAGT 451 2511- -2530 coding 104860 CGAGATAGTCGGGCCGATTG 452 2526- -2545 coding 104861 CAGACTCGGCAAAGTCGAGA 89 2541- -2560 coding 104862 CAAAGTAGACCTGCCCAGAC 453 2556- -2575 coding 104863 ACAGGGCAATGATCCCAAAG 454 2571- -2590 stop 104864 ATGTTCGTCCTCCTCACAGG 455 2586- -2605 stop 104865 GTTTGGGAAGGTTGGATGTT 456 2601- -2620 3' -UTR 104866 AAGAGGTTGAGGGTGTCTGA 457 2657 -2676 3 1 -UTR 104867 CTCTTTTTGAGCCAGAAGAG 458 2672 -2691 3 ' -UTR 104868 CCTAAGCCCCCAATTCTCTT 459 2687 -2706 3 '-UTR 104869 AGCTTGGGTTCCGACCCTAA 460 2702 -2721 3 ' -UTR 104870 TTGCTTAAAGTTCTAAGCTT 461 2717 -2736 3 • -UTR 104871 GAAGTGGTGGTCTTGTTGCT 462 2732 -2751 3 -UTR 104872 TGAATCCCAGGTTTCGAAGT 463 2747 -2766 3 -UTR 104873 CAGGCCACACATTCCTGAAT 464 2762 -2781 3 -UTR 104874 CAGCACTTCACTGTGCAGGC 465 2777 -2796 3 -UTR 104875 ATTCTTAGTGGTTGCCAGCA 466 2792- -2811 3 -UTR 104876 GAGGCCCCAGTTTGAATTCT 467 2807- -2826 3 -UTR 104877 CCCCAGTGAGTTCTGGAGGC 468 2822- -2841 3 -UTR 104878 GATCAAAGCTGTAGGCCCCA 469 2837- -2856 3 -UTR 104879 ATTCCAGATGTCAGGGATCA 470 2852- -2871 3 -UTR 104880 CTCCCTGGTCTCCAGATTCC 471 2867- -2886 3 -UTR 104881 GGCCAGAACCAAAGGCTCCC 472 2882- -2901 3 -UTR 104882 GTCCTGCAGCATTCTGGCCA 473 2897- -2916 3 -UTR 104883 GTGAGGTCTTCTCAAGTCCT 474 2912- -2931 3 -UTR 104884 TGTGTCAATTTCTAGGTGAG 475 2927- -2946 3' -UTR 104885 GGCCTAAGGTCCACTTGTGT 476 2942- -2961 3 ' -UTR 104886 ATCTGGAGAGAGGAAGGCCT 477 2957- -2976 3' -UTR 104887 AGGAAGTCTGGAAACATCTG 478 2972- -2991 3' -UTR 104888 GGGCTCCGTGTCTCAAGGAA 479 2987- -3006 3' -UTR 104889 AAATAGAGGGAGCTGGCTCC 480 3019- -3038 3' -UTR 104890 CACAAGTGCAAACATAAATA 481 3034- • 3053 3' -UTR 104891 TCCCAAATAAATACATTCAT 482 3091- • 3110 3' -UTR 104892 CAGGATACCCCGGTCTCCCA 483 3106- •3125 3' -UTR 104893 CTACATTGGGTCCCCCAGGA 484 3121- • 3140 3' -UTR 104894 GAGCCAAGGCAGCTCCTACA 485 3136- ■ 3155 3' -UTR 104895 ACGGAAAACATGTCTGAGCC 486 3151-3170 3 -UTR 104896 TTCAGCTCCGTTTTCACGGA 487 3166-3185 3 -UTR 104897 GGGAACAGCCTATTGTTCAG 488 3181-3200 3 -UTR 104898 TCAAAAGAAGGCACAGAGGC 489 3214-3233 3 -UTR 104899 TTTTAAAAAACATAATCAAA 490 3229-3248 3 -UTR 104900 TTAATCAGATAAATATTTTA 491 3244-3263 3 -UTR 104901 CATTGTTTAGACAACTTAAT 492 3259-3278 3 -UTR 104902 TGGTCACCAAATCAGCATTG 493 3274-3293 3 -UTR 104903 GCAATGAGTGACAGTTGGTC 494 3289-3308 3 -UTR 104904 GGGAGCAGAGGCTCAGCAAT 495 3304-3323 3 -UTR 104905 ATAGTAGGGCGATTACAGAC 496 3336-3355 3 -UTR 104906 ATTTCTCGCCACTGAATAGT 497 3351-3370 3 -UTR 1 Emboldened residues are 2 ' -O-methoxyethyl residues (others are 2 '-deoxy-). All 2 ' -O-methoxyethyl cytosines and 2'- deoxy cytosines residues are 5-methyl-cytosines ; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO. 1. 3 This target region is an exon-intron junction and is represented in the form, for example, I1/E2, where I, followed by a number, refers to the intron number and E, followed by a number, refers to the exon number. TABLE 32 Inhibition of Human TNF-α mRNA Expression by Chimeric (deoxy gapped) Phosphorothioate Oligodeoxynucleotides ISIS SEQ ID GENE TARGET % mRNA % mRNA No: NO: REGION EXPRESSION INHIBITION basal 0.0% induced 100.0% 0.0! 28089 69 intron 1 42.3% 57.7% 104649 251 5 -UTR 165.6% 104650 252 5 -UTR 75.8% 24.2% 104651 253 5 -UTR 58.2% 41.8% 104652 254 5 -UTR 114.5% 104653 255 5 -UTR 84.9% 15.1% 104654 256 5 -UTR 80.8% 19.2% 104655 257 5 -UTR 94.3% 5.7% 104656 258 5 -UTR 78.4% 21.6% 104657 259 5 -UTR 87.4% 12.6% 104658 260 5 -UTR 213.4% 104659 261 5 -UTR 96.3% 3.7% 104660 262 5 -UTR 153.1% 104661 263 5 -UTR 90.0% 10.0% 104662 264 5 -UTR 33.3% 66.7% 104663 265 5 -UTR 144.2% 104664 266 AUG 76.3% 23.7% 104665 267 AUG 185.3% 104666 268 AUG 67.4% 32.6% 104667 269 coding 94.3% 5.7% 104668 270 coding 63.1% 36.9% 104669 271 coding 50.8% 49.2% 104670 272 coding 43.7% 56.3% 104671 273 coding 52.2% 47.8% 104672 274 coding 51.8% 48.2% 104673 275 coding 102.3% 104674 276 coding 135.4% 104675 277 coding 83.1% 16.9% 104676 278 coding 87.5% 12.5% 104677 279 cc )ding 53.6% 46.4% 104678 280 coding 75.2% 24.8? 104679 281 coding 114.0% 104680 282 coding 142.5% 104681 283 coding 58.5% 41.5% 104682 284 coding 101.9% 104683 285 coding 77.1% 22.9% 104684 286 coding 61.0% 39.0% 104685 287 coding 65.9% 34.1% 104686 288 E2/I2 59.2% 40.8% 104687 289 coding 77.0% 23.0% 104688 290 coding 40.1% 59.9% 104689 291 coding 78.6% 21.4% 104690 292 coding 90.9% 9.1% 104691 293 coding 107.6% 104692 294 coding 63.4% 36.6% 104693 295 coding 74.1% 25.9% 104694 296 coding 108.3% 104695 297 coding 48.2% 51.8% 104696 298 coding 120.3% 104697 299 coding 45.0% 55.0% 104698 300 coding 77.1% 22.9% 104699 301 coding 143.7% 104700 302 coding 96.1% 3.9^ 104701 303 coding 106.8% 104702 304 coding 157.4% 104703 305 coding 84.3% 15.7% 104704 306 coding 182.8% 104705 307 coding 125.1% 104706 308 coding 81.8% 18.2 '- 104707 309 coding 104.8% 104708 310 coding 163.0% 104709 311 coding 95.0% 5.0% 104710 312 coding 182.1% 104711 313 coding 82.1% 17.9% 104712 314 coding 118.1% 104713 315 coding 31.1% 68.9% 104714 316 coding 90.5% 9.5% 104715 317 coding 96.7% 3.3% 104716 318 coding 180.7% 104717 93 coding 71.6% 28.4% 104718 94 coding 187.0% 104719 319 coding 88.8% 11.2% 104720 320 coding 166.5% 104721 321 coding 65.0% 35.0% 104722 322 coding 59.6% 40.4% 104723 26 coding 90.1% 9.9% 104724 323 coding 88.7% 11.3% 104725 90 coding 94.7% 5.3% 104726 91 coding 84.1% 15.9% 104727 324 coding 125.3% 104728 325 coding 221.7% 104729 326 coding 102.4% 104730 327 coding 151.6% 104731 328 coding 102.2% 104732 329 coding 53.2% 46.8% 104733 330 stop 57.0% 43.0% 104734 88 coding 119.2% 104735 331 3' -UTR 71.2% 28.8% 104736 332 stop 79.0% 21.0% 104737 333 3' -UTR 87.4% 12.6% 104738 334 stop 36.8% 63.2% 104739 335 3 -UTR 106.0% 104740 336 3 '-UTR 130.9% 104741 337 3 -UTR 79.2% 20.8% 104742 338 3 -UTR 159.0% 104743 339 3 -UTR 96.1% 3.9% 104744 340 3 -UTR 129.9% 104745 341 3 -UTR 80.2% 19.8% 104746 342 3 -UTR 168.8% 104747 343 3 -UTR 89.2% 10.8% 104748 344 3 -UTR 103.4% 104749 345 3 -UTR 89.0% 11.0% 104750 346 3 -UTR 160.0% 104751 347 3 -UTR 60.1% 39.9% 104752 348 3 -UTR 72.4% 27.6% 104753 349 3 -UTR 70.0% 30.0% 104754 350 3 -UTR 115.6% 104755 351 3 -UTR 71.7% 28.3% 104756 352 3 -UTR 91.5% 8.5% 104757 353 3 -UTR 85.6% 14.4% 104758 354 3 -UTR 97.6% 2.4% 104759 355 3 -UTR 68.6% 31.4% 104760 356 3 -UTR 182.4% 104761 357 3 -UTR 110.9% 104762 358 3 -UTR 161.4% 104763 359 3 -UTR 102.0% 104764 360 3 -UTR 113.5% 104765 361 3 -UTR 154.8% 104766 362 3 -UTR 126.4% 104767 363 3 -UTR 116.1% 104768 364 3 ' -UTR 177.7% 104769 365 3 • -UTR 89.8% 10.2% 104770 366 3 -UTR 94.3% 5.7% 104771 367 3 -UTR 191.2% 104772 368 3 -UTR 80.3% 19.7% 104773 369 3 -UTR 133.9% 104774 34 3 -UTR 94.8% 5.2% 104775 370 3 -UTR 80.6% 19.4% 104776 371 3 -UTR 90.1% 9.9% 104777 372 3 -UTR 84.7% 15.3% 104778 373 3 -UTR 121.3% 104779 374 3 -UTR 97.8% 2.2% 104780 375 3 -UTR 67.6% 32.4% 104781 376 3 -UTR 141.5% 104782 377 3 -UTR 96.5% 3.5% 104783 378 3 -UTR 153.2% 104784 379 3 -UTR 85.4% 14.6% 104785 380 3 -UTR 163.9% 104786 381 3 -UTR 82.9% 17.1% 104787 382 3 -UTR 89.7% 10.3% 104788 383 3 -UTR 103.9% 104789 384 3 -UTR 75.8% 24.2% 104790 385 3 -UTR 106.3% 104791 386 3 -UTR 165.3% 104792 387 3 -UTR 71.8% 28.2% 104793 388 3 -UTR 101.9% 104794 389 3 -UTR 70.7% 29.3% 104795 390 3 -UTR 68.8% 31.2% 104796 391 3 -UTR 93.4% 6.6% 104797 37 3 -UTR 131.7% 104798 392 3 '-UTR 89.4% 10.6% 104799 393 3 ' -UTR 89.6% 10.4% 104800 394 3 ' -UTR 89.0% 11.0% 104801 395 3 *-UTR 196.8% 104802 396 3 -UTR 189.3% 104803 397 3 -UTR 119.7% 104804 398 3 -UTR 102.4% 104805 399 3 -UTR 90.6% 9.4% 104806 400 3 -UTR 89.1% 10.9? 104807 401 3 -UTR 152.6% 104808 402 3 -UTR 96.8% 3.2% 104809 403 3 -UTR 178.8% 104810 404 3 -UTR 94.9% 5.V-, 104811 405 3 -UTR 234.4% 104812 406 3 -UTR 114.3% 104813 407 3 -UTR 153.7% 104814 408 3 -UTR 86.3% 13.7i 104815 409 3 -UTR 153.9% 104816 410 3 -UTR 79.9% 20. H 104817 411 3 -UTR 196.5% 104818 412 3 -UTR 94.3% 5.7% 104819 413 3 -UTR 143.3% 104820 414 3 -UTR 123.8% 104821 415 3 -UTR 129.2% 104822 416 5* -UTR 76.6% 23.4% 104823 417 5' -UTR 63.9% 36.1% 104824 418 5' -UTR 22.0% 78.0% 104825 419 5' -UTR 109.4% 104826 420 5' -UTR 45.2% 54.8% 104827 421 5' -UTR 68.9% 31.1% 104828 422 5' -UTR 70.9% 29.1% 104829 423 AUG 46.6% 53.4% 104830 424 coding 55.0% 45.0% 104831 425 coding 49.5% 50.5% 104832 426 coding 106.0% 104833 427 coding 23.7% 76.3% 104834 428 coding 91.8% 8.2-6 104835 429 coding 72.3% 27.7% 104836 430 coding 63.4% 36.6% 104837 431 coding 31.0% 69.0% 104838 432 coding 18.0% 82.0% 104839 433 coding 67.9% 32.1% 104840 434 coding 93.8% 6.2% 104841 435 coding 43.0% 57.0% 104842 436 coding 73.2% 26.8% 104843 437 coding 48.1% 51.9% 104844 438 coding 39.2% 60.8% 104845 439 coding 37.6% 62.4% 104846 440 coding 81.7% 18.3% 104847 441 coding 50.8% 49.2% 104848 442 coding 56.7% 43.3% 104849 443 coding 51.8% 48.2% 104850 444 coding 91.8% 8.2% 104851 445 coding 93.9% 6.1% 104852 446 coding 100.9% 104853 447 coding 67.7% 32.3% 104854 23 coding 11.0% 89.0% 104855 448 coding 62.5% 37.5% 104856 449 coding 67.8% 32.2% 104857 92 coding 28.1% 71.9% 104858 450 CCDdmg 76.2% 23.8% 104859 451 coding 52.3% 47.7% 104860 452 coding 93.6% 6.4% 104861 89 coding 79.3% 20.7% 104862 453 coding 63.1% 36.9% 104863 454 stop 64.5% 35.5% 104864 455 stop 43.2% 56.8% 104865 456 3 -UTR 83.1% 16.9% 104866 457 3 -UTR 49.4% 50.6% 104867 458 3 -UTR 49.5% 50.5% 104868 459 3 -UTR 89.6% 10.4% 104869 460 3 -UTR 21.4% 78.6% 104870 461 3 -UTR 118.0% 104871 462 3 -UTR 55.8% 44.2% 104872 463 3 -UTR 49.0% 51.0% 104873 464 3 -UTR 92.6% 7.4% 104874 465 3 -UTR 33.4% 66.6% 104875 466 3 -UTR 36.2% 63.8% 104876 467 3 -UTR 73.4% 26.6s 104877 468 3 -UTR 40.9% 59.1% 104878 469 3 -UTR 78.7% 21.3% 104879 470 3 -UTR 75.4% 24.6% 104880 471 3 -UTR 50.2% 49.8% 104881 472 3 -UTR 47.0% 53.0% 104882 473 3 -UTR 82.7% 17.3% 104883 474 3 -UTR 46.4% 53.6% 104884 475 3 -UTR 46.1% 53.9% 104885 476 3 -UTR 156.9% 104886 477 3 -UTR 102.4% 104887 478 3 -UTR 59.1% 40.9% 104888 479 3 1 -UTR 64.7% 35.3% 104889 480 3 '-UTR 83.7% 16.3% 104890 481 3 -UTR 52.9% 47.1% 104891 482 3 -UTR 87.9% 12.1% 104892 483 3 '-UTR 39.8% 60.2% 104893 484 3 -UTR 71.1% 28.9% 104894 485 3 -UTR 34.0% 66.0% 104895 486 3 -UTR 129.8% 104896 487 3 -UTR 57.6% 42.4% 104897 488 3 -UTR 49.6% 50.4% 104898 489 3 -UTR 71.7% 28.3% 104899 490 3 -UTR 101.5% 104900 491 3 -UTR 142.1% 104901 492 3 -UTR 55.9% 44.1% 104902 493 3 -UTR 85.3% 14.7% 104903 494 3 -UTR 46.0% 54.0% 104904 495 3 -UTR 59.9% 40.1% 104905 496 3 -UTR 47.2% 52.8% 104906 497 3 -UTR 56.3% 43.7% Oligonucleotides 104662 (SEQ ID NO: 264) , 104669 (SEQ ID NO: 271), 104670 (SEQ ID NO: 272), 104688 (SEQ ID NO: 290), 104695 (SEQ ID NO: 297), 104697 (SEQ ID NO: 299), 104713 (SEQ ID NO: 315), 104738 (SEQ ID NO:334), 104824 (SEQ ID NO: 418), 104826 (SEQ ID NO: 420), 104829 (SEQ ID NO: 423), 104831 (SEQ ID NO: 425), 104833 (SEQ ID NO: 427), 104837 (SEQ ID NO: 431), 104838 (SEQ ID NO: 432), 104841 (SEQ ID NO: 435), 104843 (SEQ ID NO: 437), 104844 (SEQ ID NO: 438), 104845 (SEQ ID NO: 439), 104847 (SEQ ID NO: 441), 104854 (SEQ ID NO: 23), 104857 (SEQ ID NO: 92), 104864 (SEQ ID NO: 455), 104866 (SEQ ID NO: 457), 104867 (SEQ ID NO: 458), 104869 (SEQ ID NO: 460), 104872 (SEQ ID NO: 463), 104874 (SEQ ID NO: 465), 104875 (SEQ ID NO: 466), 104877 (SEQ ID NO: 468), 104880 (SEQ ID NO: 471), 104881 (SEQ ID NO: 472), 104883 (SEQ ID NO: 474), 104884 (SEQ ID NO: 475), 104892 (SEQ ID NO: 483), 104894 (SEQ ID NO: 485), 104897 (SEQ ID NO: 488), 104903 (SEQ ID NO: 494) and 104905 (SEQ ID NO: 496) gave approximately 50% or greater reduction in TNF-α mRNA expression in this assay. Oligonucleotides 104713 (SEQ ID NO: 315), 104824 (SEQ ID NO: 418), 104833 (SEQ ID NO: 427), 104837 (SEQ ID NO: 431), 104838 (SEQ ID NO: 432), 104854 (SEQ ID NO: 23), 104857 (SEQ ID NO: 92), and 104869 (SEQ ID NO: 460) gave approximately 70% or greater reduction in TNF-α mRNA expression in this assay. EXAMPLE 23: Dose response of chimeric (deoxy gapped) antisense phosphorothioate oligodeoxynucleotide effects on TNF-α mRNA and protein levels Several oligonucleotides from the initial screen were chosen for dose response assays. NeoHk cells were grown, treated and processed as described in Example 3. LIPOFECTIN ® was added at a ratio of 3 μg/ml per 100 nM of oligonucleotide. The control included LIPOFECTIN ® at a concentration of 9 μg/ml. The human promonocytic leukaemia cell line, THP-1 (American Type Culture Collection, Manassas, VA) was maintained in RPMI 1640 growth media supplemented with 10% fetal calf serum (FCS; Life Technologies, Rockville, MD) . A total of 8 x 10 s cells were employed for each treatment by combining 50 μl of cell suspension in OPTIMEM™, 1% FBS with oligonucleotide at the indicated concentrations to reach a final volume of 100 μl with OPTIMEM™, 1% FBS. Cells were then transferred to a 1 mm electroporation cuvette and electroporated using an Electrocell Manipulator 600 instrument (Biotechnologies and Experimental Research, Inc.) employing 90 V, 1000 μF, at 13 Ω. Electroporated cells were then transferred to 24 well plates. 400 μl of RPMI 1640, 10% FCS was added to the cells and the cells were allowed to recover for 6 hrs . Cells were then induced with LPS at a final concentration of 100 ng/ml for 2 hours. RNA was isolated and processed as described in Example 3. Results with NeoHK cells are shown in Table 33 for mRNA, and Table 34 for protein. Results with THP-1 cells are shown in Table 35. Most of the oligonucleotides tested showed dose response effects with a maximum inhibition of mRNA greater than 70% and a maximum inhibition of protein greater than 85%. TABLE 33 Dose Response of NeoHK Cells to TNF-α Chimeric (deoxy gapped) Antisense Oligonucleotides SEQ ASO Gene % mRNA % mRNA ISIS # ID Target Dose Expression Inhibition NO: induced 100% 16798 128 coding 30 nM 87% 13% II 100 nM 129% II 300 nM 156% 21823 69 intron 1 30 nM 82% 18% II 100 nM 90% 10% II 300 nM 59% 41% 28088 68 intron 1 30 nM 68% 32% II 100 nM 43% 57% II 300 nM 42% 58% 28089 69 intron 1 30 nM 59% 41% II 100 nM 44% 56% II 300 nM 38% 62% 104697 299 coding 30 nM 60% 40% II 100 nM 45% 55% II 300 nM 27% 73% 104777 372 3' -UTR 30 nM 66% 34% II 100 nM 55% 45% II 300 nM 43% 57% TABLE 34 Dose Response of NeoHK Cells to TNF-α Chimeric (deoxy gapped) Antisense Oligonucleotides SEQ ASO Gene % Protein % Protein ISIS # ID Target Dose Expression Inhibition NO: induced 100.0% 16798 128 coding 30 nM 115.0% II II II 100 nM 136.0% II II II 300 nM 183.0% 28089 69 intron 1 30 nM 87.3% 12.7% II II II 100 nM 47.4% 52.6% II II II 300 nM 22.8% 77.2% 104681 283 coding 30 nM 91.3% 8.7% II II II 100 nM 62.0% 38.0% II II II 300 nM 28.5% 71.5% 104697 299 coding 30 nM 87.1% 12.9% II II II 100 nM 59.6% 40.4% II II II 300 nM 29.1% 70.9% 104838 432 coding 30 nM 91.9% 8.1% II II II 100 nM 56.9% 43.1% II II II 300 nM 14.8% 85.2% 104854 23 coding 30 nM 64.4% 35.6% II II II 100 nM 42.3% 57.7% II II II 300 nM 96.1% 3.9% 104869 460 3' -UTR 30 nM 88.9% 11.1% II II II 100 nM 56.8% 43.2% " " " 300 nM 42.3% 57.7% TABLE 35 Dose Response of LPS-Induced THP-1 Cells to Chimeric (deoxy gapped) TNF-α Antisense Phosphorothioate Oligodeoxynucleotides (ASOs) SEQ ID ASO Gene % mRNA % mRNA ISIS # NO: Target Dose Expression Inhibition induced - -- 100% 16798 128 coding 1 μM 102% -- II 3 μM 87% 13% II 10 μM 113% II 30 μM 134% 28089 69 intron 1 1 μM 39% 61% II 3 μM 79% 21% II 10 μM 91% 9% II 30 μM 63% 37% 104697 299 coding 1 μM 99% 1% II 3 μM 96% 4% II 10 μM 92% 8% II 30 μM 52% 48% 104838 432 coding 1 μM 31% 69% II 3 μM 20% 80% II 10 μM 15% 85% II 30 μM 7% 93% 104854 23 coding 1 μM 110% II 3 μM 90% 10% II 10 μM 95% 5% II 30 μM 61% 39% EXAMPLE 24: Further Optimization of Human TNF-α Antisense Oligonucleotide Chemistry Additional analogs of TNF-α oligonucleotides were designed and synthesized to find an optimum gap size. The sequences and chemistries are shown in Table 36. Dose response experiments are performed as described in Example 3. TABLE 36 Nucleotide Sequences of TNF-α Chimeric Backbone (deoxy gapped) Oligonucleotides SEQ TARGET GENE GENE ISIS NUCLEOTIDE SEQUENCE 1 ID NUCLEOTIDE TARGET NO. (5' -> 3') NO: CO- REGION ORDINATES 2 110554 GCTGATTAGAGAGAGGTCCC 432 104838 analog 110555 GCTGATTAGAGAGAGGTCCC 110556 GCTGATTAGAGAGAGGTCCC 110557 GCTGATTAGAGAGAGGTCCC 110583 GCTGATTAGAGAGAGGTCCC 110558 CTGATTAGAGAGAGGTCCC 498 1596 1614 coding 110559 CTGATTAGAGAGAGGTCCC 110560 CTGATTAGAGAGAGGTCCC 110561 CTGATTAGAGAGAGGTCCC 110562 CTGATTAGAGAGAGGTCCC 110563 CTGATTAGAGAGAGGTCCC 110564 CTGATTAGAGAGAGGTCCC 110565 CTGATTAGAGAGAGGTCCC 110566 CTGATTAGAGAGAGGTCCC 110567 CTGATTAGAGAGAGGTCCC 110584 CTGATTAGAGAGAGGTCCC 108371 CTGATTAGAGAGAGGTCC 499 1597-1614 coding 110568 CTGATTAGAGAGAGGTCC 110569 CTGATTAGAGAGAGGTCC " 110570 CTGATTAGAGAGAGGTCC " 110585 CTGATTAGAGAGAGGTCC " 110571 CTGGTTATCTCTCAGCTCCA 299 104697 analog 110572 CTGGTTATCTCTCAGCTCCA " 110573 CTGGTTATCTCTCAGCTCCA " 110586 CTGGTTATCTCTCAGCTCCA " 110574 GATCACTCCAAAGTGCAGCA 283 104681 analog 110575 GATCACTCCAAAGTGCAGCA " 110576 GATCACTCCAAAGTGCAGCA " 110587 GATCACTCCAAAGTGCAGCA " 110577 AGCTTGGGTTCCGACCCTAA 460 104689 analog 110578 AGCTTGGGTTCCGACCCTAA " 110579 AGCTTGGGTTCCGACCCTAA " 110588 AGCTTGGGTTCCGACCCTAA " 110580 AGGTTGACCTTGGTCTGGTA 315 104713 analog 110581 AGGTTGACCTTGGTCTGGTA " 110582 AGGTTGACCTTGGTCTGGTA " 110589 AGGTTGACCTTGGTCTGGTA " 110637 GTGTGCCAGACACCCTATCT 69 21823 analog 110651 GTGTGCCAGACACCCTATCT " 110665 GTGTGCCAGACACCCTATCT " 110679 GTGTGCCAGACACCCTATCT " 110693 GTGTGCCAGACACCCTATCT " 110707 GTGTGCCAGACACCCTATCT " 110590 TGAGTGTCTTCTGTGTGCCA 500 1411-1430 intron 1 110597 TGAGTGTCTTCTGTGTGCCA " 110604 TGAGTGTCTTCTGTGTGCCA " 110611 TGAGTGTCTTCTGTGTGCCA " 110618 TGAGTGTCTTCTGTGTGCCA " 110625 TGAGTGTCTTCTGTGTGCCA " 110591 GAGTGTCTTCTGTGTGCCAG 501 1410-1429 intron 1 110598 GAGTGTCTTCTGTGTGCCAG " 110605 GAGTGTCTTCTGTGTGCCAG " 110612 GAGTGTCTTCTGTGTGCCAG 110619 GAGTGTCTTCTGTGTGCCAG " 110626 GAGTGTCTTCTGTGTGCCAG " 110592 AGTGTCTTCTGTGTGCCAGA 144 100181 analog 110599 AGTGTCTTCTGTGTGCCAGA 110606 AGTGTCTTCTGTGTGCCAGA " 110613 AGTGTCTTCTGTGTGCCAGA " 110620 AGTGTCTTCTGTGTGCCAGA 110627 AGTGTCTTCTGTGTGCCAGA " 110593 GTGTCTTCTGTGTGCCAGAC 145 100182 analog 110600 GTGTCTTCTGTGTGCCAGAC 110607 GTGTCTTCTGTGTGCCAGAC " 110614 GTGTCTTCTGTGTGCCAGAC " 110621 GTGTCTTCTGTGTGCCAGAC " 110628 GTGTCTTCTGTGTGCCAGAC " 110594 TGTCTTCTGTGTGCCAGACA 146 100183 analog 110601 TGTCTTCTGTGTGCCAGACA " 110608 TGTCTTCTGTGTGCCAGACA " 110615 TGTCTTCTGTGTGCCAGACA " 110622 TGTCTTCTGTGTGCCAGACA " 110629 TGTCTTCTGTGTGCCAGACA " 110595 GTCTTCTGTGTGCCAGACAC 147 100184 analog 110602 GTCTTCTGTGTGCCAGACAC " 110609 GTCTTCTGTGTGCCAGACAC 110616 GTCTTCTGTGTGCCAGACAC " 110623 GTCTTCTGTGTGCCAGACAC " 110630 GTCTTCTGTGTGCCAGACAC " 110596 TCTTCTGTGTGCCAGACACC 148 100185 analog 110603 TCTTCTGTGTGCCAGACACC " 110610 TCTTCTGTGTGCCAGACACC " 110617 TCTTCTGTGTGCCAGACACC " 110624 TCTTCTGTGTGCCAGACACC " 110631 TCTTCTGTGTGCCAGACACC " 110632 CTTCTGTGTGCCAGACACCC 149 100186 analog 110646 CTTCTGTGTGCCAGACACCC " 110660 CTTCTGTGTGCCAGACACCC " 110674 CTTCTGTGTGCCAGACACCC " 110688 CTTCTGTGTGCCAGACACCC " 110702 CTTCTGTGTGCCAGACACCC " 110633 TTCTGTGTGCCAGACACCCT 150 100187 analog 110647 TTCTGTGTGCCAGACACCCT " 110661 TTCTGTGTGCCAGACACCCT " 110675 TTCTGTGTGCCAGACACCCT " 110689 TTCTGTGTGCCAGACACCCT " 110703 TTCTGTGTGCCAGACACCCT " 110634 TCTGTGTGCCAGACACCCTA 151 100188 analog 110648 TCTGTGTGCCAGACACCCTA " 110662 TCTGTGTGCCAGACACCCTA " 110676 TCTGTGTGCCAGACACCCTA " 110690 TCTGTGTGCCAGACACCCTA " 110704 TCTGTGTGCCAGACACCCTA " 110635 CTGTGTGCCAGACACCCTAT 152 100189 analog 110649 CTGTGTGCCAGACACCCTAT " 110663 CTGTGTGCCAGACACCCTAT " 110677 CTGTGTGCCAGACACCCTAT " 110691 CTGTGTGCCAGACACCCTAT " 110705 CTGTGTGCCAGACACCCTAT 110636 TGTGTGCCAGACACCCTATC 153 100190 analog 110650 TGTGTGCCAGACACCCTATC " 110664 TGTGTGCCAGACACCCTATC " 110678 TGTGTGCCAGACACCCTATC " 110692 TGTGTGCCAGACACCCTATC " 110706 TGTGTGCCAGACACCCTATC " 110638 TGTGCCAGACACCCTATCTT 154 100191 analog 110652 TGTGCCAGACACCCTATCTT " 110666 TGTGCCAGACACCCTATCTT " 110680 TGTGCCAGACACCCTATCTT " 110694 TGTGCCAGACACCCTATCTT " 110708 TGTGCCAGACACCCTATCTT 110639 GTGCCAGACACCCTATCTTC 155 100192 analog 110653 GTGCCAGACACCCTATCTTC " 110667 GTGCCAGACACCCTATCTTC 110681 GTGCCAGACACCCTATCTTC " 110695 GTGCCAGACACCCTATCTTC " 110709 GTGCCAGACACCCTATCTTC " 110640 TGCCAGACACCCTATCTTCT 156 100193 analog 110654 TGCCAGACACCCTATCTTCT " 110668 TGCCAGACACCCTATCTTCT " 110682 TGCCAGACACCCTATCTTCT 110696 TGCCAGACACCCTATCTTCT " 110710 TGCCAGACACCCTATCTTCT " 110641 GCCAGACACCCTATCTTCTT 157 100194 analog 110655 GCCAGACACCCTATCTTCTT " 110669 GCCAGACACCCTATCTTCTT " 110683 GCCAGACACCCTATCTTCTT " 110697 GCCAGACACCCTATCTTCTT " 110711 GCCAGACACCCTATCTTCTT " 110642 CCAGACACCCTATCTTCTTC 158 100195 analog 110656 CCAGACACCCTATCTTCTTC " 110670 CCAGACACCCTATCTTCTTC " 110684 CCAGACACCCTATCTTCTTC " 110698 CCAGACACCCTATCTTCTTC " 110712 CCAGACACCCTATCTTCTTC " 110643 CAGACACCCTATCTTCTTCT 159 100196 analog 110657 CAGACACCCTATCTTCTTCT " 110671 CAGACACCCTATCTTCTTCT " 110685 CAGACACCCTATCTTCTTCT " 110699 CAGACACCCTATCTTCTTCT " 110713 CAGACACCCTATCTTCTTCT 110644 AGACACCCTATCTTCTTCTC 160 100197 analog 110658 AGACACCCTATCTTCTTCTC " 110672 AGACACCCTATCTTCTTCTC " 110686 AGACACCCTATCTTCTTCTC " 110700 AGACACCCTATCTTCTTCTC " 110714 AGACACCCTATCTTCTTCTC " 110645 GACACCCTATCTTCTTCTCT 161 100198 analog 110659 GACACCCTATCTTCTTCTCT " 110673 GACACCCTATCTTCTTCTCT " 110687 GACACCCTATCTTCTTCTCT " 110701 GACACCCTATCTTCTTCTCT " " 110715 GACACCCTATCTTCTTCTCT " " 1 Emboldened residues are 2 ' -methoxyethoxy residues (others are 2 '-deoxy-). All 2 ' -methoxyethoxy cytidines and 2'- deoxycytidines are 5-methyl-cytidines; all linkages are phosphorothioate linkages. 2 Co-ordinates from Genbank Accession No. X02910, locus name "HSTNFA", SEQ ID NO . 1. Example 25: Effect of TNF-α antisense oligonucleotides in TNF-α transgenic mouse models The effect of TNF-α antisense oligonucleotides is studied in transgenic mouse models of human diseases. Such experiments can be performed through contract laboratories (e.g. The Laboratory of Molecular Genetics at The Hellenic Pasteur Institute, Athens, Greece) where such transgenic mouse models are available. Such models are available for testing human oligonucleotides in arthritis (Keffer, J., et al . , EMBO J. , 1991, 10 , 4025-4031) and multiple sclerosis (Akassoglou, K. , et al., J. Immunol . , 1997, 158, 438-445) models. A model for inflammatory bowel disease is available for testing mouse oligonucleotides (Kontoyiannis, D., et al . , Immuni ty, 1999, 10, 387-398). Briefly, litters of the appropriate transgenic mouse strain are collected and weighed individually. Twice weekly from birth, oligonucleotide in saline is administered intraperitoneally or intravenously. Injections continue for 7 weeks. Each week the animals are scored for manifestations of the appropriate disease. After the final treatment, the mice are sacrificed and histopathology is performed for indicators of disease as indicated in the references cited for each model.

Claims: What is claimed is: 1. An oligonucleotide 8 to 30 nucleotides in length comprising a nucleotide sequence complementary to an intron of a nucleic acid encoding human tumor necrosis factor-α, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor-α. 2. The oligonucleotide of claim 1 wherein said intron is intron 1 of a nucleic acid encoding human tumor necrosis factor-α. 3. The oligonucleotide of claim 2 comprising SEQ ID NO: 66, SEQ ID NO: 69, SEQ ID NO: 149 or SEQ ID NO: 157. 4. The oligonucleotide of claim 1 wherein said intron is intron 2 of a nucleic acid encoding human tumor necrosis factor-α. 5. The oligonucleotide of claim 1 wherein said intron is intron 3 of a nucleic acid encoding human tumor necrosis factor-α. 6. The oligonucleotide of claim 5 comprising SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 84. 7. The oligonucleotide of claim 1 which contains at least one phosphorothioate intersugar linkage. 8. The oligonucleotide of claim 1 which has at least one 2 ' -O-methoxyethyl modification. 9. The oligonucleotide of claim 1 which contains at least one 5-methyl cytidine. 10. The oligonucleotide of claim 8 in which every 2'- O-methoxyethyl modified cytidine residue is a 5-methyl cytidine. 11. The oligonucleotide of claim 9 in which every cytidine residue is a 5-methyl cytidine. 12. The oligonucleotide of claim 1 which contains at least one methylene (methylimino) intersugar linkage. 13. A composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent. 14. The composition of claim 13 wherein said pharmaceutically acceptable carrier or diluent comprises a lipid or liposome. 15. A method of modulating the expression of human tumor necrosis factor-α in cells or tissue comprising contacting said cells or tissue with the oligonucleotide of claim 1. 16. A method of reducing an inflammatory response of human cells comprising contacting said human cells with the oligonucleotide of claim 1. 17. A method of treating a human having a disease or condition associated with tumor necrosis factor-α comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide of claim 1. 18. The method of claim 17 wherein said administering is through oral delivery. 19. The method of claim 17 wherein the disease or condition is associated with overexpression of tumor necrosis factor-α. 20. The method of claim 19 wherein said disease or condition is an inflammatory or autoimmune disease or condition. 21. The method of claim 20 wherein said inflammatory or autoimmune disease or condition is diabetes, inflammatory bowel disease, multiple sclerosis, pancreatitis, rheumatoid arthritis, hepatitis, atopic dermatitis or allograft rejection. 22. The method of claim 19 wherein said disease or condition is an infectious disease. 23. The method of claim 22 wherein said infectious disease is hepatitis. 24. An oligonucleotide complementary to a nucleic acid molecule encoding human tumor necrosis factor-α, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor-α and comprises SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:39, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 102, SEQ ID NO: 264, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:290, SEQ ID NO:297, SEQ ID NO: 299, SEQ ID NO: 315, SEQ ID NO: 334, SEQ ID NO: 418, SEQ ID NO:420, SEQ ID NO:423, SEQ ID NO:425, SEQ ID NO:427, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:435, SEQ ID NO:437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 458, SEQ ID NO: 460, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 468, SEQ ID NO: 471, SEQ ID NO:472, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:483, SEQ ID NO:485, SEQ ID NO:488, SEQ ID NO:494 or SEQ ID NO:496. 25. The oligonucleotide of claim 24 which contains at least one phosphorothioate intersugar linkage. 26. The oligonucleotide of claim 24 which has at least one 2 ' -O-methoxyethyl modification. 27. The oligonucleotide of claim 24 which contains at least one 5-methyl cytidine. 28. The oligonucleotide of claim 26 in which every 2 ' -O-methoxyethyl modified cytidine residue is a 5-methyl cytidine. 29. The oligonucleotide of claim 27 in which every cytidine residue is a 5-methyl cytidine. 30. The oligonucleotide of claim 24 which contains at least one methylene (methylimino) intersugar linkage. 31. A composition comprising the oligonucleotide of claim 24 and a pharmaceutically acceptable carrier or diluent. 32. The composition of claim 31 wherein said pharmaceutically acceptable carrier or diluent comprises a lipid or liposome. 33. A method of modulating the expression of human tumor necrosis factor-α in cells or tissue comprising contacting said cells or tissue with the oligonucleotide of claim 24. 34. A method of reducing an inflammatory response of human cells comprising contacting said human cells with the oligonucleotide of claim 24. 35. A method of treating a human having a disease or condition associated with tumor necrosis factor-α comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide of claim 24. 36. The method of claim 35 wherein said administering is through oral delivery. 37. The method of claim 35 wherein the disease or condition is associated with overexpression of tumor necrosis factor-α. 38. The method of claim 37 wherein said disease or condition is an inflammatory or autoimmune disease or condition. 39. The method of claim 38 wherein said inflammatory or autoimmune disease or condition is diabetes, inflammatory bowel disease, multiple sclerosis, pancreatitis, rheumatoid arthritis, atopic dermatitis or allograft rejection. 40. The method of claim 39 wherein said disease or condition is an infectious disease. 41. The method of claim 40 wherein said infectious disease is hepatitis. 42. An oligonucleotide 8 to 30 nucleotides in length comprising a nucleotide sequence complementary to a nucleic acid encoding human tumor necrosis factor-α, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor-α, and has at least one 2 ' -O-methoxyethyl modification. 43. An oligonucleotide 8 to 30 nucleotides in length comprising a nucleotide sequence complementary to a nucleic acid encoding human tumor necrosis factor-α, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor-α, and contains at least one 5-methyl cytidine. 44. The oligonucleotide of claim 42 in which every 2 ' -O-methoxyethyl modified cytidine residue is a 5-methyl cytidine . 45. The oligonucleotide of claim 43 in which every cytidine residue is a 5-methyl cytidine. 46. An oligonucleotide 8 to 30 nucleotides in length comprising a nucleotide sequence complementary to a nucleic acid encoding human tumor necrosis factor-α, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor-α, and which contains at least one methylene (methylimino) intersugar linkage. 47. An antisense oligonucleotide capable of modulating gene expression in adipose tissue. 48. The antisense oligonucleotide of claim 47 which is targeted to human tumor necrosis factor-α. 49. A method of modulating the expression of a selected gene product in adipose tissue comprising contacting said adipose tissue with an antisense compound targeted to said selected gene. 50. The method of claim 49 wherein said selected gene product is tumor necrosis factor-α. 51. A method of modulating the function of a selected nucleic acid sequence in adipose tissue comprising contacting said adipose tissue with an antisense compound targeted to said selected nucleic acid sequence. 52. The method of claim 51 wherein said selected nucleic acid sequence encodes tumor necrosis factor-α. 53. A method of treating a human having a disease or condition associated with expression of a selected nucleic acid sequence in adipose tissue comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound targeted to said selected nucleic acid sequence. 54. The method of claim 53 wherein said adminstering is through oral delivery. 55. A method of reducing the blood glucose level in a human comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide of claim 1. 56. A method of reducing the blood glucose level in a human comprising administering to said animal a therapeutically or prophylactically effective amount of an oligonucleotide of claim 24.

Inventors: BAKER BRENDA F, BENNETT C FRANK, BUTLER MADELINE M, SHANAHAN WILLIAM J JR, BAKER, BRENDA, F., BENNETT, C., FRANK, BUTLER, MADELINE, M., SHANAHAN, WILLIAM, J., JR.
Applicants: BAKER BRENDA F, BENNETT C FRANK, BUTLER MADELINE M, ISIS PHARMACEUTICALS INC, SHANAHAN WILLIAM J JR, BAKER, BRENDA, F., BENNETT, C., FRANK, BUTLER, MADELINE, M., ISIS PHARMACEUTICALS, INC., SHANAHAN, WILLIAM, J., JR.
Application year: 1999
Main classification: C12Q1
IPC codes: A61K31, A61K38, A61K48, A61P1, A61P3, A61P17, A61P29, A61P31, C07H21, C12N15